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ABSTRACT 
 
Prep1 is an homeodomain transcription factor belonging to the MEINOX 
subfamily of the TALE (three amino acid loop extension) proteins. Prep1 forms 
DNA-independent dimeric complexes with all isoforms of the Pbx homeodomain 
transcription factor, enhancing target specificity and regulatory function. Recently, 
we have shown that Prep1 deficiency in mice induces protection from diabetes and 
increased insulin sensitivity in muscle tissue through a mechanism which involves 
increased protein and mRNA levels of the glucose transporter (GLUT)-4 and the 
PPAR gamma coactivator-1 alpha (PGC-1 . Since PGC-1 promotes the 
gluconeogenesis in hepatic tissue, I have studied the role of Prep1 in regulating 
insulin signaling in liver of Prep1 hypomorphic (Prep1i/i, Prep1i/+) mice, which 
expressed respectively only 5-7% and 55-57% of protein. Despite the results 
obtained in muscle tissue, Prep1i/i and Prep1i/+ mice did not show changes in 
PGC-1 protein and mRNA levels, but surprisingly they have an improved 
insulin-stimulated phosphorylation of IR and IRS-1/2. This is paralleled by an 
increase of glycogen content and a reduction of Glucose-6-phosphatase and 
PEPCK expression. Western blot analysis and qRT-PCR experiments displayed a 
gene-dosage dependent reduction of protein and mRNA levels of SHP1 and SYP 
tyrosine phosphatases in liver extracts of Prep1i/i, Prep1i/+ mice. In parallel, the 
overexpression of Prep1 and Pbx1 in and HepG2 (Human Hepatoma cell line) 
cells induced insulin resistance by increasing the protein content and mRNA 
expression of SHP1 and SYP phosphatases, which were paralleled by an inhibition 
of insulin-stimulated phosphorylation of IR, IRS-1/2 and glycogen accumulation. 
Interestingly, the overexpression of an inactive form of Prep1 (Prep1HR1), lacking 
of the interaction site between Prep1 and Pbx1, did not impair SHP1 and SYP 
expression and insulin-signaling in HepG2 cells. Moreover, in Prep1 
overexpressing cells, antisense silencing of SHP1 but not that of SYP rescued 
insulin-dependent IR phosphorylation and glycogen accumulation. Finally, ChIP 
and Re-Chip experiments pointed out that the dimeric complex Prep1-Pbx1 bound 
specific sequences upstream the ATG codon of SYP and SHP1 genes (-625bp and 
-2113bp respectively) suggesting a direct gene regulation. Luciferase assays 
confirmed that the regions upstream SYP and SHP1 genes, were functionally 
activated by  Prep1 and Pbx1 overexpression. Thus, the dimeric complex Prep1-
Pbx1 directly regulates the gene expression of SYP and SHP1 tyrosine 
phosphatases by promoting insulin-resistance in liver cells. 
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BACKGROUND 
 
1. Type 2 Diabetes: an overview 
Diabetes mellitus, long considered a disease of minor significance to world health, 
is now taking its place as one of the main threats to human health in the 21
st
 
century. The past two decades have seen an explosive increase in the number of 
people diagnosed with diabetes worldwide. The global figure of people with 
diabetes is set to rise from the current estimate of 220 million (2010) to 300 
million in 2025 (Figure 1).  
 
 
 
 
Figure 1. Number of people with diabetes (millions) for 2000 and 2010 (top and middle values 
respectively), and the percentage increase. Data adapted from the reference Amos et al. 1997. 
 
There are two main forms of diabetes. Type 1 diabetes is due primarily to 
autoimmune-mediated destruction of pancreatic cells, resulting in absolute 
insulin deficiency. Its frequency is low compared to type 2 diabetes, which 
accounts for over 90% of cases globally. Type 2 diabetes is characterized by both 
insulin resistance and impaired insulin secretion. People with type 2 diabetes are 
not dependent on exogenous insulin, but may require the hormone for the control 
of glucose homeostasis if this is not achieved with diet alone or with oral 
hypoglycaemic agents.  
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2. Glucose homeostasis 
 
Despite periods of feeding and fasting, plasma glucose levels remain in a narrow 
range between 66 and 110 mg/dl in normal individuals. This tight control is 
governed by the balance between glucose absorption from the intestine, production 
by the liver and uptake and metabolism by peripheral tissues such as skeletal 
muscle and adipose tissue (Saltiel and Kahn 2001). 
Carbohydrate metabolism is regulated by several hormone, and also by 
sympathetic and parasympathetic nervous system (Table 1). The increasing 
glucose concentration after feeding (80/150 mg/dl) determines an increase of 
insulin release from pancreatic beta cells and a decrease of glucagon release from 
pancreatic alpha cells (Kahn 1994). Insulin lowers blood glucose levels both by 
suppressing glycogenolysis and gluconeogenesis in the liver (thereby decreasing 
hepatic glucose output), and by stimulating glucose uptake into skeletal muscle 
and adipose tissue. These actions are opposed by the “counter-regulatory” 
hormones, which are secreted continuously but whose release is enhanced during 
physiological “stress” (Pickup 2005). 
Thus, the correct efficiency of pancreatic beta cells in insulin synthesis and 
secretion and its action on the liver, skeletal muscle and adipose tissue represents a 
key factor in glucose homeostasis maintenance.  
 
 Liver 
gluconeogenesis 
 
Glycogenolysis 
 
HGO 
Pheripheral Glucose 
Uptake 
Insulin ↓↓ ↓↓ ↓↓ ↑↑ 
Glucagon ↑↑§ ↑↑ ↑↑ - 
Catecholamines ↑↑*§ ↑ ↑↑ ↓ 
Growth hormone ↑* - ↑ ↓ 
Cortisol ↑*§ - ↑ ↓ 
  
Table 1. Main hormones affecting glucose metabolism. 
*Indirect enhancement of gluconeogenesis due to increased supply of glycerol and fatty acids by 
enhanced lypolisis. 
§Increased gluconeogenesis by effects on hepatic enzymes and increased supply of glucogenic 
amino acids. 
 
 
 
3. Insulin 
 
Insulin is the most potent anabolic hormone known. Secreted by pancreatic beta 
cells in response to increase of plasmatic glucose and amino acids levels after 
feeding, insulin promotes the synthesis and storage of carbohydrates, lipid, 
proteins and inhibits their degradation and release into the circulation. Insulin 
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stimulates the uptake of glucose, amino acids and fatty acids into cells, and 
increases the expression and activity of enzymes that catalyse glycogen, lipid and 
protein synthesis (Saltiel and Kahn 2001). 
Insulin increases glucose uptake in muscle and fat, and inhibits hepatic glucose 
production (glycogenolysis and gluconeogenesis), thus serving as primary 
regulator of blood glucose concentration. Insulin also stimulates cell growth and 
differentiation, promotes the storage of substrates in fat, liver and muscle by 
stimulating lipogenesis, glycogen and protein synthesis, and inhibiting lipolysis, 
glycogenolysis and protein breakdown (Figure 2) (Saltiel and Kahn 2001). 
 
Figure 2. The regulation of metabolism by the insulin. 
Insulin promotes the synthesis and storage of carbohydrates, lipids and proteins. Indeed, insulin 
stimulates the uptake of glucose, amino acids and fatty acids into cells, and increases the 
expression or activity of enzymes that catalyse glycogen, lipid and protein synthesis, while 
inhibiting the activity or expression of those that catalyse degradation. 
 
 
 
4. Insulin signaling system 
 
Insulin action is mediated through the insulin receptor (IR), a transmembrane 
glycoprotein with intrinsic protein tyrosine kinase activity. The insulin receptor 
belongs to a subfamily of receptor tyrosine kinases that includes the insulin-like 
growth factor (IGF)-I receptor and the insulin receptor-related receptor (IRR). 
These receptors are tetrameric proteins consisting of two α- and two β-subunits 
that function as allosteric enzymes where the α-subunit inhibits the tyrosine kinase 
activity of the β-subunit. Insulin binding to the α-subunit leads to derepression of 
the kinase activity of the β-subunit followed by trans-phosphorylation of the β-
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subunits and conformational change of the α subunits that further increases kinase 
activity (Patti and Kahn 1998). Several intracellular substrates of the insulin 
receptor kinases have been identified (Figure 3). Four of these belong to the family 
of insulin-receptor substrate (IRS) proteins (White et al. 1998). Other substrates 
include Gab-1 and isoforms of Shc10 (Pessin and Saltiel 2000). The 
phosphorylated tyrosines in these substrates act as “docking sites” for proteins that 
contain SH2 (Srchomology-2) domains. Many of these SH2 proteins are adaptor 
molecules, such as the p85 regulatory subunit of PI(3)K and Grb2, or CrkII, which 
activate small G proteins by binding to nucleotide exchange factors. Others are 
themselves enzymes, including the phosphotyrosine phosphatase SYP and the 
cytoplasmic tyrosine kinase Fyn. PI(3)K has a pivotal role in the metabolic and 
mitogenic actions of insulin (Shepherd et al. 1995). It consists of a p110 catalytic 
subunit and a p85 regulatory subunit that possesses two SH2 domains that interact 
with tyrosinephosphorylated motifs in IRS proteins (Myers MG Jr et al. 1992). 
PI(3)K catalyses the phosphorylation of phosphoinositides on the 3-position to 
produce phosphatidylinositol-3-phosphates, especially PtdIns(3,4,5)P3, which bind 
to the pleckstrin homology (PH) domains of a variety of signaling molecules 
thereby altering their activity, and subcellular localization (Lietzke et al. 2000). 
Phosphotidylinositol-3-phosphates regulate three main classes of signaling 
molecules: the AGC family of serine/threonine protein kinases, the Rho family of 
GTPases, and the TEC family of tyrosine kinases. PI(3)K also might be involved 
in regulation of phospholipase D, leading to hydrolysis of phosphatidylcholine and 
increases in phosphatidic acid and diacylglycerol. The best characterized of the 
AGC kinases is phosphoinositide-dependent kinase 1 (PDK1), one of the serine 
kinases that phosphorylates and activates the serine/threonine kinase Akt/PKB 
(Alessi et al. 1997). Akt/PKB has a PH domain that also interacts directly with 
PtdIns(3,4,5)P3, promoting membrane targeting of the protein and catalytic 
activation. Akt/PKB has a pivotal role in the transmission of the insulin signal, by 
phosphorylating the enzyme GSK-3, the forkhead transcription factors and cAMP 
response element-binding protein. 
Other AGC kinases that are downstream of PI(3)K signaling include the atypical 
PKCs, such as PKC-δ. Akt/PKB and/or the atypical PKCs are required 
for insulin stimulated glucose transport (Standaert et al. 1997). 
As is the case for other growth factors, insulin stimulates the mitogen activaed 
protein (MAP) kinase extracellular signal regulated kinase (ERK) (Figure 3). This 
pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which 
in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless 
(SOS) exchange protein to the plasma membrane for activation of Ras. The 
activation of Ras also requires stimulation of the tyrosine phosphatase SYP, 
through its interaction with receptor substrates such as Gab-1 or IRS-1/2. Once 
activated, Ras operates as a molecular switch, stimulating a serine kinase cascade 
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through the stepwise activation of Raf, MEK and ERK. Activated ERK can 
translocate into the nucleus, where it catalyses the phosphorylation of transcription 
factors such as p62TCF, initiating a transcriptional programme that leads to 
cellular proliferation or differentiation (Boulton et al. 1991). 
 
 
 
Figure 3. Signal transduction in insulin action. 
The insulin receptor is a tyrosine kinase that undergoes autophosphorylation, and catalyses the 
phosphorylation of cellular proteins such as members of the IRS family, Shc and Cbl. Upon 
tyrosine phosphorylation, these proteins interact with signaling molecules through their SH2 
domains, resulting in a diverse series of signaling pathways, including activation of PI(3)K and 
downstream PtdIns(3,4,5)P3-dependent protein kinases, Ras and the MAP kinase cascade. These 
pathways act in a concerted fashion to coordinate the regulation of vesicle trafficking, protein 
synthesis, enzyme activation and inactivation, and gene expression, which results in the regulation 
of glucose, lipid and protein metabolism. 
 
4.1 Regulation of glycogen synthesis  
Insulin stimulates glycogen accumulation through a coordinated increase in 
glucose transport and glycogen synthesis. The hormone activates glycogen 
synthase by promoting its dephosphorylation, through the inhibition of kinases 
such as PKA or GSK-3 and activation of protein phosphatase 1 (PP1) (Cross et al. 
1994). Upon its activation downstream of PI(3)K, Akt phosphorylates and 
inactivates GSK-3, decreasing the rate of phosphorylation of glycogen synthase, 
thus increasing its activity state (Cross et al. 1994). Insulin does not activate PP1 
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globally, but rather specifically targets discrete pools of the phosphatase, primarily 
increasing PP1 activity localized at the glycogen particle. The compartmentalized 
activation of PP1 by insulin is due to glycogen-targeting subunits, which serve as 
'molecular scaffolds', bringing together the enzyme directly with its substrates 
glycogen synthase and phosphorylase in a macromolecular complex, and in the 
process exerting profound effects on PP1 substrate-specific activity (Newgard et 
al. 2000). 
Four different proteins have been reported to target PP1 to the glycogen particle. 
Despite a proposed common function, no two targeting subunits share more than 
50% sequence homology, and this is largely confined to the PP1- and glycogen-
binding regions. Overexpression of these scaffolding proteins in cells or in vivo 
results in a marked increase in cellular glycogen levels (Newgard et al. 2000). 
Although the mechanism by which insulin activates glycogen-associated PP1 
remains unknown, inhibitors of PI(3)K block this effect, suggesting that 
PtdIns(3,4,5)P3-dependent protein kinases are involved. These scaffolding proteins 
have a critical permissive role in the hormonal activation of the enzyme, perhaps 
interacting with additional proteins that regulate the interaction of PP1 with 
glycogen synthase and phosphorylase 
 
4.2 Regulation of gluconeogenesis 
Insulin inhibits the production and release of glucose by the liver by blocking 
gluconeogenesis and glycogenolysis (Figure 4). This occurs through a direct effect 
of insulin on the liver (Micheal et al. 2000), as well as by indirect effects of insulin 
on substrate availability (Bergman and Ader 2000). Insulin can also influence 
glucose metabolism indirectly by changes in free fatty acids generated from 
visceral fat, the so called “single gateway” hypothesis (Bergman 1997). Because 
visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal 
there is little suppression of lipolysis by the hormone in this fat depot. The 
resulting direct flux of fatty acids derived from these fat cells through the portal 
vein to the liver can stimulate glucose production, thus providing a signal for both 
insulin action and insulin resistance in the liver. 
Insulin directly controls the activities of a set of metabolic enzymes by 
phosphorylation or dephosphorylation and also regulates the expression of genes 
encoding hepatic enzymes of gluconeogenesis and glycolysis (Pilkis and Granner 
1992). It inhibits the transcription of the gene encoding phosphoenolpyruvate 
carboxykinase, the rate-limiting step in gluconeogenesis (Sutherland et al. 1996). 
The hormone also decreases transcription of the genes encoding fructose-1,6-
bisphosphatase and glucose-6-phosphatase, and increases transcription of 
glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic 
enzymes such as fatty acid synthase and acetyl-CoA carboxylase. Although the 
transcription factors that control the expression of these genes have remained 
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elusive, new data suggest a potential role for the forkhead family of transcription 
factors through phosphorylation by Akt-related protein kinases (Nakae et al. 
1999), and the PPAR  co-activator PGC-1  (Yoon et al. 2001). 
 
Figure 4. The regulation of glucose metabolism in the liver. 
In the hepatocyte, insulin stimulates the utilization and storage of glucose as lipid and glycogen, 
while repressing glucose synthesis and release. This is accomplished through a coordinated 
regulation of enzyme synthesis and activity. Insulin stimulates the expression of genes encoding 
glycolytic and fatty-acid synthetic enzymes (in blue), while inhibiting the expression of those 
encoding gluconeogenic enzymes (in red). These effects are mediated by a series of transcription 
factors and co-factors, including sterol regulatory element-binding protein (SREBP)-1, hepatic 
nuclear factor (HNF)-4, the forkhead protein family (Fox) and PPAR  co-activator 1 (PGC1). The 
hormone also regulates the activities of some enzymes, such as glycogen synthase and citrate lyase 
(in green), through changes in phosphorylation state. GK, glucokinase; Glucose-6-P, glucose-6-
phosphate; G6Pase, glucose-6-phosphatase; F-1,6-Pase, fructose-1,6-bisphosphatase; PEPCK, 
phosphoenolpyruvate carboxykinase; PFK, phosphofructokinase; PK, pyruvate kinase; ACC, 
acetyl-CoA carboxylase; FAS, fatty-acid synthase. 
 
 
5. Inhibition of insulin signaling: the tyrosine phosphatases 
Insulin signaling cascade may be attenuated by several enzymes, one of the most 
important are the protein tyrosine phosphatases (PTPases), which catalyse the 
rapid dephosphorylation of the receptor and its substrates. A number of PTPases 
have been identified that catalyse dephosphorylation of the insulin receptor in 
vitro, some of which are expressed in insulin-responsive cells, or up-regulated in 
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states of insulin resistance. Most attention has focused on the cytoplasmic 
phosphatases PTP-1B, SYP and SHP1. 
PTP-1B was the first mammalian PTP identified and purified to homogeneity. This 
phosphatase is widely expressed and localizes predominantly to the ER through a 
cleavable proline-rich C-terminal segment (Frangioni et al. 1992). 
In addition to the IR, IRS-1 might also be a substrate of PTP-1B because in the 
presence of Grb2, IRS-1 dephosphorylation by PTP-1B is accelerated (Goldstein 
et al. 2000). 
Knockout of PTP-1B leads to increased insulin induced IR phosphorylation in 
liver and muscle but not adipose tissue. IRS-1 phosphorylation was also increased 
in muscle, but it is unclear whether this is because IRS-1 is a substrate of PTP-1B, 
or an increased IR activity in knockout mice. Furthermore, PTP-1B-deficient mice 
are hypersensitive as assayed by oral glucose tolerance tests, intraperitoneal 
insulin tolerance tests, and blood levels of glucose and insulin (Elchebly et al. 
1999). Importantly, PTP-1B–/– mice are also resistant to diet-induced obesity, due 
in part to a decrease in fat cell mass and increased energy expenditure (Klaman et 
al. 2000).  
SYP is a widely expressed PTP that contains two N-terminal SH2 domains, a C-
terminal catalytic domain and a C-terminal segment containing two tyrosyl 
phosphorylation sites (Feng 1999). In contrast to many other growth factor 
receptor associated PTPs, SYP does not seem to dephosphorylate the receptor. 
However, Kuhne et al. proposed that the binding of IRS-1 to SYP enhances its 
phosphatase activity toward IRS-1, resulting in its dephosphorylation in vivo. 
Genetic studies in mice indicate that SYP is required for embryonic development 
(Saxton et al. 1997). SYP heterozygous knockout mice are viable, and in these 
mice, plasma insulin and glucose uptake were normal (Arrandale et al. 1996). 
Moreover tyrosine phosphorylation of IR and IRS-1 from muscle tissue was 
similar to that of wild-type controls. These results suggest that SYP might play a 
minor role in the metabolic effects of insulin.  In another approach, when SYP is 
expressed in a transgenic mouse model, an insulin-resistant phenotype is observed 
that implicates the PTP as a negative regulator of insulin signaling (Maegawa et al. 
1999). 
Another PTP recently linked to insulin signaling and glucose metabolism is SHP1. 
Insulin may stimulate the phosphorylation and activation of SHP1, presumably by 
a direct association between SHP1 and the insulin receptor (Uchida et al. 1994, 
Bousquet et al. 1998). Mice expressing a catalytically defective SHP1 (Ptpn6
me-
v/me-v
) are markedly glucose tolerant and insulin sensitive compared to wild-type 
controls, as a result of enhanced insulin receptor signaling to IRS-PI3K-Akt in 
liver and muscle and increased phosphorylation of CEACAM1 (Dubois et al. 
2006). This metabolic phenotype of Ptpn6
me-v/me-v  
mice is recapitulated in normal 
mice through adenoviral expression of a dominant-negative inactive form of SHP1 
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in the liver or hepatic knockdown of SHP1 by small hairpin (sh)RNA mediated 
gene silencing, confirming a crucial role for SHP1 in negatively modulating 
insulin action and clearance in the liver, thereby regulating whole-body glucose 
homeostasis (Dubois et al. 1996). 
Thus, the combination of these effects implicate PTP-1B, SYP and SHP1 as  
crucial therapeutic targets in diabetes and obesity. 
 
 
6. Type 2 diabetes and insulin-resistance 
 
T2D accounts for 90% of all forms of diabetes and is most common in people 
older than 45 who are overweight. However, as a consequence of increased obesity 
among young people, it is becoming more common in children and young adults. 
T2D is a heterogeneous syndrome with many possible causes. This is due to the 
interaction of environmental factors with a genetic susceptibility to the disease 
(Table 3), and it is becoming more and more evident that the relative contribution 
of genes and environment can differ considerably, even among individual whose 
clinical phenotype is similar (Diabetes Atlas 2006). The maintenance of normal 
glucose homeostasis depends on a precisely balanced and dynamic interaction 
between tissue sensitivity to insulin and insulin secretion. Type 2 diabetes 
develops because of defects in both insulin secretion and action, both of these with 
a genetic as well as an acquired component. Thus, T2D is made up of different 
forms each of which is characterized by variable degrees of insulin- resistance and 
beta cell dysfunction, and which together lead to hyperglycaemia. Insulin 
resistance, typically, is an early feature of T2D. It results from a genetically 
determined reduction in insulin sensitivity, compounded by exposure to the 
environmental factors, which further impair insulin action. Major sites of insulin 
resistance include liver and the peripheral tissues, skeletal muscle and fat. In 
muscle and fat, insulin resistance is manifested by decreased glucose uptake; in 
muscle, it impaired utilization of glucose by non-oxidative pathways as well as by 
decrease in glucose oxidation; in the liver, insulin resistance leads to failure of 
insulin to suppress hepatic glucose production, which is followed by glycogen 
breakdown and particularly by gluconeogenesis (Pickup 2005) (Figure 4). 
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Figure 4. Insulin resistance on tissue targets. 
The main sites of insulin resistance are liver and the peripheral tissue, skeletal muscle and fat. 
insulin resistance is manifested by decreased glucose uptake in muscle and fat, and by failure 
of insulin to suppress hepatic glucose production in the liver. 
 
The beta cell dysfunction, the other key component of T2D pathophysiology, 
involves a relatively selective defect in the ability of glucose to provoke insulin 
secretion by beta cells, a temporal irregularity in the pulse and oscillations of 
insulin secretion, and a loss of the tight coupling between pulses of insulin 
secretion and pulse in glucose. This defect accounts for the failure of beta cells to 
compensate for increasing insulin-resistance and for the ultimate development of 
overt hyperglycaemia. The disease often remains asymptomatic and undetected for 
years. People with type 2 diabetes are not completely dependent on exogenous 
insulin, but may require the hormone for the control of blood glucose levels if this 
is not achieved with diet alone, regular exercise or with oral hypoglycaemic 
agents.  
But if T2 diabetic people are not diagnosed or successfully treated, may develop 
“diabetic complications”, such as micro-vascular complications (disease of the 
small blood vessels) including retinopathy, neuropathy and nephropathy, and 
macro-vascular complications (disease of the large blood vessels) including 
coronary heart disease, myocardial infarction and stroke. 
 
 
7. Genes in type 2 diabetes 
 
As mentioned above, insulin resistance and impaired beta cell function are the 
prominent features of T2D, and they are contributed by genetic and environmental 
factors. These factors might affect either the process of insulin signal transmission 
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across the plasma membrane and/or the biochemical pathways allowing glucose 
uptake and metabolism by the cells, or might affect the pathways regulating beta 
cell function, including those for beta cell compensation. While several 
environmental factors have been identified, discovery and characterization of the 
genes involved in T2D has been an arduous task and has proceeded slowly. In the 
past 10 years, indeed, geneticists have devoted a large amount of effort to finding 
T2D genes. These efforts have included many candidate-gene studies, extensive 
efforts to fine map linkage signals, and an international linkage consortium that 
was perhaps the best example of a multi-centre collaboration in common-disease 
genetics (Genome Wide Association Studies, GWAS). Of these efforts, only the 
candidate-gene studies produced unequivocal evidence for common variants 
involved in T2D. These are the E23K variant in the potassium inwardly-rectifying 
channel, subfamily J, member 11 (KCNJ11) gene (Nielsen, et al. 2003), the P12A 
variant in the peroxisome proliferator-activated receptor-γ (PPARG) gene 
(Altshuler, et al. 2000), and common variation in the transcription factor 2, hepatic 
(TCF2) (Gudmundsson, et al. 2007) and the Wolfram syndrome 1 (WFS1)10 genes 
(Sandhu, et al. 2007). All of these genes encode proteins that have strong 
biological links to diabetes. Rare, severe mutations in these four genes cause 
monogenic forms of diabetes, and two of them are targets of antidiabetic therapies: 
KCNJ11 encodes a component of a potassium channel with a key role in beta cell 
physiology and it is targeted by the sulphonylurea class of drugs; PPARG encodes 
a transcription factor involved in adipocyte differentiation and it is targeted by the 
thiazolidinedione class of drugs (Figure 5). A common amino-acid polymorphism 
(Pro12Ala) in peroxisome proliferator activated receptor-γ (PPARγ) has been 
associated with T2D. People homozygous for the Pro12 allele are more insulin 
resistant than those having one Ala12 allele and have a 1.25-fold increased risk of 
developing diabetes. Moreover, there is also evidence for interaction between this 
polymorphism and fatty acids, thereby linking this locus with diet (Altshuler, et al. 
2000). In 2006, by far the most spectacular recent development in the field of 
multifactorial T2D genetics has been the identification of TCF7L2 (encoding 
transcription factor 7-like 2) as the most important T2D-susceptibility gene to date 
(Owen and McCarthy 2007). The estimate of effect size (an odds ratio for T2D of 
1.4-fold per allele) was identified in an intronic SNP with uncertain functional 
credentials (rs7903146). TCF7L2 variation is strongly associated with rates of 
progression from impaired glucose tolerance to diabetes (with a hazard ratio of 
1.55 between homozygote groups). TCF7L2 is widely expressed and involved in 
the Wnt signaling cascade. Most studies suggest that the predominant intermediate 
phenotype associated with TCF7L2 variation is impaired insulin secretion, 
consistent with the replicated observation that the TCF7L2 association is greater 
among lean than obese T2D subjects. Early mechanistic hypotheses have focused 
on the known role of TCF7L2 in the gut, postulating the involvement of impaired 
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release of glucagon-like peptide-1 (an important islet secretagogue), reduced beta 
cell mass or intrinsic beta cell dysfunction. Body mass index data and some 
preliminary associations with leptin and ghrelin levels, however, could point 
towards a central mechanism. TCF7L2 result was encouraging for two reasons. 
First, this study analysed more than 200 markers across a region of linkage on 
chromosome 10q, but the variants that were found to alter risk did not explain the 
linkage signal, suggesting that a non-candidate-gene or region-based association 
effort (such as a GWAS) could work. Second, TCF7L2 was a completely 
unexpected gene showing that a genome-wide approach could uncover previously 
unexpected disease pathways. 
IPF-1/PDX-1 (Insulin Promoter Factor-1/Pancreatic and Duodenal Homeobox-1) 
is an homeodomain-containing transcription factor involved in pancreatic 
development, transcriptional regulation of a number of beta cell genes including 
insulin, glucokinase, islet amyloid polypeptide and GLUT2, and mediation of 
glucose-stimulated insulin gene transcription. Mutations in the heterozygous state 
are associated with MODY4 (Maturity Onset Diabetes in the Young 4), a non-
ketotic monogenic form of diabetes mellitus, characterized by an autosomal 
dominant mode of inheritance, onset usually before 25 years of age and a primary 
defect in pancreatic beta cell function. IPF-1 mutations have also been discovered 
in a small fraction of patients with typical adult-onset type 2 diabetes. Subjects 
with heterozygous mutations in IPF-1 demonstrated reduced insulin secretory 
responses to glucose and glucagon-like peptide-1, consistent with a defect in the 
signaling pathways that regulate secretion in the beta cell and/or a defect in beta 
cell mass.  
Functional and cooperative interactions between IPF-1 and another family of 
homeodomain-containing transcription factors named TALE (Three Aminoacid  
Loop Extension) is required for several genes regulation. Recently, TALE 
homeoproteins have been related to diabetes and insulin-resistance (Kim et al. 
2002, Oriente et al 2008).  
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Figure 5. Effect sizes of the 11 common variants confirmed to be involved in type 2 diabetes 
risk. 
The x axis shows the year when published evidences reached the levels of statistical confidence 
that are now accepted as necessary for genetic association studies. CDKAL1, CDK5 regulatory 
subunit associated protein 1-like 1; CDKN2, cyclin-dependent kinase inhibitor 2A; FTO, fat mass 
and obesity-associated; HHEX, haematopoietically expressed homeobox; IDE, insulin-degrading 
enzyme; IGF2BP2, insulin-like growth factor 2 mRNA-binding protein 2; KCNJ11, potassium 
inwardly-rectifying channel, subfamily J, member 11; PPARG, peroxisome proliferator-activated 
receptor-γ gene; SLC30A8, solute carrier family 30 (zinc transporter), member 8; TCF2, 
transcription factor 2, hepatic; TCF7L2, transcription factor 7-like 2 (T-cell specific, HMg-box); 
WFS1, Wolfram syndrome 1. 
 
 
8. TALE proteins 
 
TALE proteins are a family of homeodomain transcription factors which play an 
important role in the regulation of many genes involved in the organogenesis and 
differentiation of several organs and tissues. In order to promote these events, 
TALE proteins may cooperate with HOX proteins as multi molecular complexes 
(Featherstone 2003, Moens and Selleri 2006).  
TALE proteins display a well preserved DNA binding structure of approximately 
60 amino acids named homeodomain. This region is composed of three alpha 
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helices and a flexible N-terminal arm. The homeodomain interacts with the DNA 
through the third helix making base-specific contacts in the major groove of DNA 
and through the N-terminal arm which contacts the minor groove of DNA. 
Between the first and the second alpha helices of the homeodomain there is a 3 
aminoacid, virtually represented  by a proline (P) - tyrosine (Y) - proline (P) in 
positions 24-26, loop extension (TALE) responsible for the interaction with HOX 
proteins (Featherstone 2003, Moens and Selleri 2006). 
TALE homeodomain proteins are divided into two groups: the PBC family, 
including the vertebrate Pbx proteins, fly Extradenticle and worm Ceh-20, and the 
MEIS family, including vertebrate Meis and Prep, fly Homothorax (Hth) and 
worm Unc-62 (Figure 6) (Moens and Selleri 2006). 
Recent papers have shown the molecular mechanisms through Prep1 and Pbx1 
TALE proteins may induce insulin-resistance in animal models (Oriente et al. 
2008). These studies have confirmed a novel role of these transcription factors in 
the pathogenesis of the disease.  
 
 
 
Figure 6. Phylogeny and structure TALE homeodomain proteins.  
TALE homeodomain proteins are divided into two groups: the PBC family, including the 
vertebrate Pbx proteins, fly Extradenticle and worm Ceh-20, and the MEIS family, including 
vertebrate Meis and Prep, fly Homothorax (Hth) and worm Unc-62. Orange letters indicate mouse 
proteins, purple lettering indicates their zebrafish orthologs. Although in some cases the orthology 
assignments are not clear (as for pbx2 and pbx4), genetic rescue experiments in zebrafish have 
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suggested that the different pbx genes are functionally identical. Similar information is not yet 
available with regard to mammalian Pbx genes. 
 
8.1 Pbx1 protein 
 
Pbx1 (pre-B cell leukemia transcription factor) protein is a small ubiquitous 
molecule which belongs to the PBC family. Pbx1, was identified at the (1;19) 
chromosomal breakpoint present in 25% of pediatric pre-B cell leukemias. Further 
studies have shown Pbx1 interact with other transcription factors and play an 
important role in the embryonic development (Nourse et al. 1990).  
Pbx1 protein is characterized by the homeodomain region including the three 
aminoacid loop extension which interacts with the specific sequences of the HOX 
transcription factors. Near the amino terminal region there are two highly 
homologous regions named PBC- A and -B important for the protein-protein 
interaction (Figure 7) (Burglin 1997, Piper et al. 1999, Moens and Selleri 2006,). 
The relevance of Pbx1 on glucose metabolism has been underlined by several 
studies involving knock-out mice. Pbx1−/− mice die during the embryogenesis and 
show pancreatic hypoplasia and impaired differentiation of endocrine cells. 
Moreover, Pbx1-/+ mice have low levels of plasma insulin which contributes to 
the onset of a severe glucose intolerance. In these animals, the levels of PDX-1, a 
gene involved in the transcription of the insulin gene and the genesis of the 
pancreas, is strongly reduced, indicating that Pbx1 is important for its expression 
and most probably assessing the molecular events responsible for the observed 
phenotype (Selleri et al. 2001, Brendolan et al. 2005, Kim et al. 2002). The 
different actions of the Pbx class of proteins are also determined by the large 
numbers of interactors, including homeodomain and non-homeodomain proteins. 
The affinity of Pbx to the other cofactors or the specific DNA sequences mostly 
depends on the interaction with another important TALE homeoprotein named 
Prep1 (Moens and Selleri 2006).   
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Figure 7. Structure of TALE homeodomain proteins. Prototype members of PBC and MEIS 
classes are shown here. “a” and “b” refer to splice isoforms of Pbx and Meis proteins. All TALE 
homeodomain proteins contain a divergent homeodomain (HD) containing a 3 amino acid loop 
extension (TALE) between the first and second α-helices. The TALE motif virtually always bears a 
proline (P)–tyrosine (Y)–proline (P) in positions 24–26) and contacts the hexapeptide motif of Hox 
proteins. Pbx proteins contain an additional DNA-contacting α-helix (α4; HCM) C-terminal to the 
canonical homeodomain. The PBC-A and PBC-B domains are conserved among Pbx, Exd and 
Ceh-20, and the PBC-A domain interacts with Meis/Prep proteins. Conversely, the HM1 and HM2 
domains conserved among Meis/Prep proteins and are required for interactions with Pbx proteins. 
Posterior Hox genes of the AbdB subclass are unusual in that they can interact directly with Meis 
proteins via a C-terminal region (CTD) of Meis including the homeodomain; this region is 
indicated by a black bar. 
 
8.2 Prep1 protein 
 
Prep1 (Pbx regulating protein1) is an ubiquitary homeodomain transcription factor 
belonging to the MEINOX subfamily of TALE proteins (Berthelsen et al. 1998) 
mapping on the chromosome 21q.22.3.  Prep1 forms DNA-independent dimeric 
complexes with the Pbx homeodomain trancription factor, enhancing target 
specificity and regulatory function (Berthelsen et al. 1998). It is a 64kDa protein 
which can localize both in cytoplasm and in the nucleus (Berthelsen et al. 1998). 
The protein shows two well-preserved domain named HR (HM in the figure) 
(homology region) 1 and 2 necessary for interaction with its partners and DNA  
binding. Near the C-terminus there is the homeodomain region necessary for DNA 
binding and between the first and the second alpha helices of the homeodomain 
there is the 3 aminoacid loop extension (TALE) (Figure 7) (Berthelsen et al. 
1998). Prep1 can form heterodimers with PBC proteins and, in particular, the HR1 
and HR2 domains of Prep bind the PBC-A sequence of Pbx1. Heterodimerization 
with Pbx appears to be essential to translocate Prep1 into the nucleus. On the other 
hand, Prep1 dimerization prevents nuclear export and the proteasomal degradation 
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of Pbx prolonging its half-life (Berthelsen et al. 1999). Heterodimerization of 
Prep1 with Pbx forms the UEF-3 (urokinase Enhancer factor-3) transcription 
factor which is important in the regulation of  the expression of the interleukin 3 
(IL-3), stromelysin and urokinase plasminogen activator (uPA), a protease 
involved in fibrinolysis, innate and adaptive immunity (Berthelsen et al. 1996). In 
addition, co-expression of Pbx1-Prep1 inhibits the glucagon gene transcription in 
non-glucagon-producing cells, (Herzig et al. 2000). Prep1 and Pbx1 can form 
ternary complexes with the pancreatic and duodenal homeobox 1 (PDX-1). 
Functional and cooperative interactions between PDX-1, Pbx, and Prep1 is 
required for somatostatin gene transcription (Goudet et al. 1999). Several studies 
on Prep1 have been conducted in different kind of animals. In mice, a null Prep1 
mutation results in early lethality (E7.5) (Fernandez and Blasi, unpublished data), 
precluding a study of the Prep1 role(s) in later developmental processes. An 
insertion of a retroviral vector in the first intron of the Prep1 gene results in a 
hypomorphic mutation (Prep1i/i) that exhibits variable penetrance and 
expressivity. Most Prep1i/i embryos die between E17.5 and P0, although about 1/4 
of these escape embryonic lethality. The mice escaping embryonic lethality show 
T-cell development anomalies (Penkov). In addition, erythropoiesis and 
angiogenesis are impaired, with liver hypoplasia, decreased hematocrit, anemia, 
and delayed erythroid differentiation together with a decrease in capillary 
formation. Prep1i/i embryos also display major eye anomalies and exhibit 
decreased levels of Pbx1, Pbx2, and Meis1 proteins as well as decreased 
expression of cMyb and Pax6, consistent with the hematopoietic and eye 
phenotype, respectively (Ferretti et al. 2006).  
 
8.2.1 Prep1 and diabetes  
 
In our laboratory we have recently evidenced an important role of Prep1 in 
pancreas development and in glucose homeostasis (Oriente et al. 2008). Prep1 
hypomorphic (Prep1i/i) mice, which expressed only 5-7% of Prep1, show smaller 
islets consistent with a 35% decrease of both glucagon and insulin secretion. Pbx1 
levels are reduced in Prep1i/i mice, emphasizing the idea that Prep1 hierarchically 
acts upstream in the network regulating pancreas development by controlling the 
levels of Pbx1. However, Prep1i/i animals exhibit enhanced sensitivity to insulin 
action in skeletal muscle and are protected from developing streptozotocin-
induced diabetes. Measurement of the expression of several proteins playing an 
important role in insulin sensitivity and glucose disposal, like the insulin receptor 
(IR), Insulin Receptor Substrate-1 and -2, Akt/PKB, PKC zeta, ERK1/2 and Pbx1, 
have revealed no significant differences in Prep1i/i and control mice. In contrast, 
the  levels of glucose transporter (GLUT4) and the PPAR gamma coactivator-1 
alpha (PGC-1  are markedly increased, while the p160 Myb-binding protein 
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(p160), a molecule which is known to inhibit the PGC-1 -mediated glucose 
transport and competes with Pbx1 to bind Prep1, is reduced in hypomorphic mice. 
These findings raises the possibility that, in the skeletal muscle, Prep1 down-
regulation results in activation of the glucose transport machinery by decreasing 
p160 levels. These effects have been confirmed by transfecting Prep1, Pbx1 and 
p160 cDNA in differentiating L6 skeletal muscle cells. Overexpression of Prep1 
reduces the levels of PGC1  and GLUT4 and increases p160 protein expression in 
these cells, while overexpression of Pbx1 boosts the levels of PGC1  and GLUT4. 
Thus, Pbx1 and Prep1 have opposite effects on insulin-dependent glucose disposal 
by muscle. Prep1-mediated p160 expression is, at least in part, post-translational. 
In addition, a direct delivery of p160 cDNA in the muscle of Prep1 hypomorphic 
mice mimics the effect of Prep1, decreasing PGC-1  and GLUT4 expression. On 
the basis of the results, Prep1 might be considered as a new gene involved in the 
pathogenesis of type 2 diabetes and insulin-resistance. 
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AIMS OF THE STUDY 
 
This thesis concerns the role of Prep1 homeodomain protein on liver insulin action 
in animal models and in hepatic cultured cells. In particular, I focused my attention 
on the effects mediated by the transcription complex Prep1-Pbx1. 
Data produced in our lab indicate that Prep1 deficiency may positively modulate 
the intracellular pool of GLUT4 in muscle tissue by enhancing the transcription of 
the PPAR gamma coactivator-1 alpha (PGC-1 gene (Oriente et al. 2008). This 
molecular effects lead to improvement of insulin sensitivity in this tissue. 
As mentioned before, liver gluconeogenesis is a major process determining 
insulin-regulated glucose metabolism. Expression of the gluconeogenic enzymes 
G6Pase and PEPCK is regulated not only by the recruitment or modifications of 
transcription factors but also of co-activator proteins, including PGC-1  (Yoon et 
al. 2001). Whether and how Prep1 affects glucose metabolism in liver is unknow 
at the present but important to clarify in order to elucidate how Prep1 regulates 
insulin-dependent glucose metabolism at the whole-body level. 
Thus, my purpose was to investigate whether the deficiency of Prep1 in liver 
might reproduce the molecular changes in PGC-1α levels observed in muscle 
tissue and modulate the glucose metabolism in this organ. 
To achieve my aim I have studied glucose metabolism and insulin action in liver 
of Prep1 hypomorphic mice (Prep1i/i) and focused my attention on the possible 
genes which could have been regulated by the transcription complex Prep1-Pbx1. 
Secondly, I have investigated whether the overexpression of Prep1 might induce 
insulin-resistance in hepatic cells (HepG2) and confirm the molecular mechanism 
by which Prep1 acts. 
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MATERIALS AND METHODS 
 
Materials 
Media, sera, antibiotics for cell culture and the lipofectamine reagent were from 
Invitrogen (Grand Island, NY). The Prep1, PGC-1 , actin, IR, Pbx1, SYP, SHP1 
and PTP-1B antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). The pY, IRS1, IRS2, antibodies were from Upstate Biotechnolgy (Lake 
Placid, NY). Protein electrophoresis, Real Time PCR, luciferase assay reagents 
were purchased from Bio-Rad (Richmond, VA), Western blotting and ECL 
reagents from Amersham Biosciences (Arlington Heights, IL). All other chemicals 
were from Sigma (St. Louis, MO). 
 
 
 
Generation of Prep1 hypomorphic mice 
 
Prep1 targeted mice were generated by gene trapping by Lexikon Genetics, Inc. 
(The Woodlands, Texas) and have been previously described (15, 38). In the 
experiments reported in this paper, heterozygous mice were backcrossed with 
wild-type (WT) C57BL/6 for 4 generations. All animal handling conformed to 
regulations of the Ethics Committee on Animal Use of H. S. Raffaele (IACUC 
permission number 207). Hepatic tissue samples were collected rapidly after mice 
were sacrificed by pentobarbitone overdose. Tissues were snap frozen in liquid 
nitrogen and stored at –80°C for subsequent western blotting. 
 
 
 
Determination of glycogen content and pyruvate tolerance test 
 
Hepatic tissue samples or HepG2 cells were homogenized in 0.1% SDS 
(1ml/24mg tissue or 1 ml/culture plate) using a glass-teflon potter and incubated 
30’ at 37°C. After the incubation, 500 l of lysates were used for the assay. The 
glycogen was precipitated by adding ½ vol. (250 l) saturated Na2SO4 and 1.2 vol. 
(600 l) 95% EtOH and incubating 30’ in ice. To isolate the glycogen, the samples 
were centrifuged at 4°C 20’ at 1000rpm. The glycogen pellet was completely dried 
in vacuum conditions by SPEED VAC centrifugation and resuspended in 1ml 
dH2O. Finally, the samples were transferred into glass tubes and mixed with 1ml 
5% Aqueous Phenol (Sigma-Aldrich) and 5ml 98% H2SO4 to disrupt the 
molecules of glycogen. The samples were incubated 10’ at RT and subsequently 
20’ at 30° C in agitation. The molecules of glucose derived by the intracellular 
pool of glycogen were quantified by spectrophotometric analysis (reading 490 
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nm), compared with a linear standard curve of standard glycogen samples and 
normalized for the proteins content of the samples. For the pyruvate tolerance test, 
mice deprived of food for 16 hours were injected intraperitoneally with pyruvate 
dissolved in saline (2g/Kg) and venous blood glucose was drawn by tail clipping at 
0, 30, 60, 90, and 120 min and measured with a glucometer (A. Menarini 
Diagnostics). 
 
 
 
Cell culture procedures and transfection  
 
HepG2 hepatoma cells and NMuLi mouse liver cells were cultured at 37°C in 
Dulbecco’ s modified Eagle’ s medium (DMEM) supplemented with 10% fetal 
bovine serum, 2% L-glutamine, 10,000 units/ml penicillin, 10,000 g/ml 
streptomycin. Transient transfection of Prep1, Prep1HR, p160 and Pbx1 plasmid 
sDNAs or SYP and SHP1 phosphorothioate antisense oligonucleotides were 
performed by the Lipofectamine reagent according to the manufacturer’s 
instruction. For these studies, 60-80% confluent cells were washed twice with 
Optimem (Invitrogen) and incubated for 8h with 3-5 g of plasmid construct or 
with 250nM of oligonucleotides and 45-60 l of lipofectamine reagent. In 
transient transfection, the medium was then replaced with DMEM with 10% fetal 
bovine serum and cells further incubated for 15 h before being assayed. In stably 
transfection individual G418-resistant clones were selected by the limiting dilution 
technique (G418 effective dose, 0.8 mg/ml). 
 
 
Western blot analysis and immunoprecipitation procedures 
 
Tissue samples were homogenized in a Polytron (Brinkman Instruments, N.Y.) in 
20 ml T-PER reagent/gram of tissue according to manufacture (Pierce, IL). After 
centrifugation at 10,000 rpm for 5 minutes, supernatant was collected. Cells were 
solubilized in lysis buffer (50 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 10 
mmol/L EDTA, 10 mmol/l Na4P2O7, 2 mmol/L Na3VO4, 100 mmol/L NaF, 10% 
glycerol, 1% Triton X-100, 1 mmol/L PMSF, 10 mg/ml aprotinin) for 1 h at 4C 
and lysates were centrifuged at 5,000g for 20 min. Total or immunoprecipitated 
homogenates were separated by SDS-PAGE and transferred on 0.45 m 
Immobilon-P membranes. Upon incubation with primary and secondary 
antibodies, immunoreactive bands were detected by ECL according to the 
manufacturer's instructions. 
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Real-Time RT-PCR analysis  
 
Total cellular RNA was isolated from liver and HepG2 cells by using the RNeasy 
kit (QIAGEN Sciences, Germany), according to manufacturer’s instructions. 1 g 
of tissue or cell RNA was reverse-transcribed using Superscript II Reverse 
Transcriptase (Invitrogen, CA). PCR reactions were analyzed using SYBR Green 
mix (Invitrogen, CA). Reactions were performed using Platinum SYBR Green 
qPCR Super-UDG using an iCycler IQ multicolor Real Time PCR Detection 
System (Biorad, CA). All reactions were performed in triplicate and -actin was 
used as an internal standard.  
 
 
 
Chromatin immunoprecipitation (ChIP) and Re-ChIP assay  
 
The cross-linking solution, containing 1% formaldehyde, was added directly to 
cell culture media. The fixation proceeded for 10 min and was stopped by the 
addition of glycine to a final concentration of 125 mM. nMuLi  cells were rinsed 
twice with cold phosphate buffered saline plus 1 mM phenylmethylsulfonyl 
fluoride and then scraped. Cells were collected by centrifugation at 800 X g for 5 
min at 4 °C. Cells were swelled in cold cell lysis buffer containing 5 mM PIPES 
(pH 8.0), 85 mM KCl, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 
and inhibitors mixture (Sigma) and incubated on ice for 10 min. Nuclei were 
precipitated by microcentrifugation at 2000Xg for 5 min at 4 °C, resuspended in 
nuclear lysis buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.8% 
SDS, 1 mM phenylmethylsulfonyl fluoride and inhibitors mixture (Sigma), and 
then incubated on ice for 10 min. Samples were broken by sonication into 
chromatin fragments of an average length of 500/ 1000 bp and then 
microcentrifuged at 16,000 X g for 10 min at 4 °C. The sonicated cell supernatant 
was diluted 8-fold in chromatin immunoprecipitation (ChIP) dilution buffer 
containing 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris- HCl 
(pH 8.0), and 167 mM NaCl and precleared by adding salmon sperm and 
conjugating protein at equimolar concentration for 90 min at 4 °C. Precleared 
chromatin from 1X106 cells was incubated with 1 g of polyclonal antibody (anti-
Prep1) or no antibody and rotated at 4 °C for 16 h. Immunoprecipitates were 
washed five times with radioimmune precipitation assay buffer containing 10 mM 
Tris-HCl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 
0.1% SDS, 140 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride, twice with 
LiCl buffer containing 0.25 M LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 
mM EDTA, 10 mM Tris-HCl (pH 8.0), and then 3 times with TE (10 mM Tris-
HCl (pH 8.0), 1 mM EDTA). Before the first wash, the supernatant from the 
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reaction lacking primary antibody was saved as total input of chromatin and was 
processed with the eluted immunoprecipitates beginning at the cross-link reversal 
step. Immunoprecipitates were eluted by adding 1% SDS, 0.1 M NaHCO3, and 
reverse cross-linked by the addition of NaCl to a final concentration of 200 mM 
and by heating at 65 °C for at least 4 h. Recovered material was treated with 
proteinase K, extracted with phenol-chloroform-isoamyl alcohol (25:24:1), and 
precipitated. The pellets were resuspended in 30 l of TE and analyzed by PCR 
using specific primers for the analyzed regions. The input sample was resuspended 
in 30 l of TE and diluted 1:10 before PCR. For ReChIP assay, 
immunoprecipitates with the first antibody were eluted in 50 ml of DTT 10 mM, 
diluted 10-fold in ChIP Dilution Buffer supplemented with protease inhibitors, and 
immunoprecipitated with the second antibody. Following immunoprecipitation, 
samples are processed as described above for ChIP assay and eluted DNA 
amplified by PCR with specific oligos. 
 
 
 
Luciferase assay 
 
The mouse genomic region of SHP1 n.2 (-2113/-1778) was amplified by PCR 
from genomic mouse DNA isolated from murine liver cell line (NmuLi cells). The 
following primers were used: F: 5’-KpnI- TCGGTGTGAGATCGGTACAA-3’ 
and R:5’-SacI- TCCGAGTTGGTGTCTCAGTG-3’ (SHP1 n°2), (where SacI and 
KpnI indicate the restriction sites added to the sequence). The amplified regions 
were cloned in Plg3 promoter vector (Promega) by SacI and KpnI cloning 
strategy. To examine the effect of Prep1 and Pbx1 on SHP1 n°2 regions, HeLa 
cells were cotransfected with 2 g of SHP1 n.2 promoter vector together with 
different amounts of Prep1 and Pbx1 expression vectors. Total DNA content (up to 
4 g/plate) was normalized to the empty vector devoid of Prep1 and Pbx1 coding 
sequence. 48 h after transfection luciferase activity was measured by a commercial 
luciferase assay kit (Promega). Values were normalized for beta-galactosidase.  
 
 
 
Statistical procedures  
 
Data were analysed with the Statview software (Abacus-concepts) by one-factor 
analysis of variance. P values of less than 0.05 were considered statistically 
significant.  
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RESULTS AND DISCUSSION 
 
Prep1 deficiency may positively modulate the intracellular pool of GLUT4 in 
muscle tissue by enhancing the transcription of the PPAR gamma coactivator-1 
alpha (PGC-1 gene (Oriente et al. 2008). These molecular changes have been 
observed in Prep1 hypomorphic mice (Prep1i/i) and lead to increase insulin 
sensitivity in this tissue.  
To address the role of PGC-1  in liver of Prep1 hypomorphic mouse, I analyzed 
the hepatic protein and mRNA levels of PGC-1  in Prep1i/i and i/+ mice.  
Surprisingly, No significant differences were detected in Prep1 hypomorphic and 
control littermates (Figure 8a, b). 
 
 
Figure 8. Role of PGC-1  in the liver of the Prep1 hypomorphic mice. Livers from Prep1 
hypomorphic and control mice were dissected, solubilized and subjected to Western blot analysis 
with PGC-1 and actin antibodies. Blots were revealed by ECL and autoradiography and bands 
quantified by densitometric analysis. Each bar represents the mean ± SD of duplicate 
determinations in 10 mice/group (a). The abundance of mRNA for PGC-1  was determined by RT-
PCR analysis of total RNA isolated from liver of the hypomorphic and control mice, using beta-
actin as internal standard. Each bar represents the mean ± SD of four independent experiments 
performed in 8 mice/genotype (b). 
 
In order to study the hepatic glucose metabolism of Prep1 hypomorphic mice, I 
profiled the initial steps of the insulin signaling cascade by measuring the protein 
expression and the activation levels (tyrosine phosphorylation) of the insulin 
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receptor (IR) and the IRSs proteins (IRS1-2). In particular, I activated the insulin 
signaling cascade by injecting control and hypomorphic mice intraperitoneally 
with insulin 0.75mU/g. Subsequently, mice were sacrificed and 
immunopreciptiation assays were performed with specific antibodies against the 
phosphorylated tyrosines of IR and IRS1-2 in liver extracts. No change was 
evidenced in either IR, IRS1 or IRS2 total protein levels, while, tyrosine 
phosphorylation of all these proteins was significantly increased in Prep1 
hypomorphic mice, in a gene dosage-dependent manner, compared to wild type 
mice (Figure 9). 
 
 
 
Figure 9. Insulin signaling in liver of Prep1 hypomorphic mice. Protein lysates (250 g) from 
liver tissue of WT and Prep1 hypomorphic mice, injected with insulin 0.75mU/g, were 
immunoprecipitated with IR, IRS-1 or IRS-2 antibodies followed by blotting with phosphotyrosine, 
IR, IRS-1 or IRS-2 antibodies. Actin antibodies were used for the loading control normalization. 
The autoradiograph is representative of four independent experiments.  
 
It is known that the effect of insulin on liver cells is to block the gluconeogenesis 
by reducing the expression of G6Pase and PEPCK and induce glycogen storage. I 
assessed whether the enhanced insulin signaling might affect the final steps of 
insulin pathway by measuring the gene expression of G6Pase and PEPCK and by 
checking the gluconeogenesis and the glycogen storage after insulin stimulation. 
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As shown in figure 10a, b, Prep1i/i mice display 2-fold increase in glycogen 
accumulation and the effect of the insulin on the downregulation of G6Pase and 
PEPCK genes is stronger compared to control mice. 
 
 
 
 
 
Figure 10. Insulin-stimulated glycogen storage and G6Pase/PEPCK gene expression in Prep1 
hypomorphic mice.  Prep1 hypomorphic and control mice (n = 12 mice/group) were 
intraperitoneally injected with insulin (0.75 mU/g body weight) for 2 hours, then the liver was 
isolated and glycogen content was measured as described in material and methods. Bars represent 
the means ± SD of determinations in 12 mice/group. Asterisks indicate statistically significant 
differences (**, p < 0.01) (a). The abundance of mRNA for G6Pase and PEPCK was determined 
by real-time RT-PCR analysis of total RNA isolated from liver of the hypomorphic and control 
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mice, using beta-actin as internal standard. Each bar represents the mean ± SD of four independent 
experiments performed in 8 mice/genotype (b). 
 
G6Pase and PEPCK are key enzymes in the hepatic regulation of glucose output 
and gluconeogenesis respectively. I have evaluated if the reduction of G6Pase and 
PEPCK observed in the liver of Prep1 hypomorphic mice in response to insulin 
might have modified the rate of glucose output/gluconeogenesis. One of the test, 
widely used in literature, to study this aspect of glucose metabolism is the pyruvate 
tolerance test (PTT), because, pyruvate gets into the hepatic cells and it is quickly 
converted into glucose. I have measured the blood glucose levels during 2 hours 
after the Na pyruvate administration. As shown in figure 11 the profile of blood 
glucose of Prep1i/+ mice indicated that the sensitivity to pyruvate-induced 
hyperglycemia was significantly lower in Prep1i/+. 
 
 
Figure 11. Pyruvate tolerance test in Prep1i/+ mice. B. WT and Prep1i/+ mice (n=12 
mice/group) were fasted for 16 hours, injected with pyruvate (2g/Kg) and plasma glucose 
concentrations were quantified at the indicated times. Data points represent the means ± SD of 
results obtained from each group of mice. Asterisks denote statistically significant differences (*, p 
< 0.05; **, p < 0.01). 
 
Thus, the reduction of G6Pase and PEPCK expression observed in the liver of 
Prep1 hypomorphic mice, reflects the lower glycemia observed during the 
experiment. The enhanced insulin signaling of these mice may contribute to reduce 
pyruvate-induced hyperglycemia in Prep1 hypomorphic mice compared to WT 
mice. This last set of results indicate that Prep1 deficiency may significantly 
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modify insulin action in hepatic tissue by improving either the first steps of the 
cascade and the functional effects of the hormone. Moreover, the network 
involved in Prep1 action in liver is completely different from the muscle, since  
PGC-1 is not involved. 
To investigate the molecular mechanisms of this phenotype, I evaluated the 
activation and the protein levels of several serine/threonine kinase proteins 
involved in the negative regulation of insulin action. No difference was detected 
for members of PKC isoforms (  and ), ERK1/2 and JNK between WT and 
Prep1
 
hypomorphic mice (data not shown). Also GRB10, an adapter protein which 
interact with IR and reduces insulin-stimulated tyrosine phosphorylation of IRS1 
and IRS2, was unchanged (data not shown). The insulin-dependent liver 
glucoregulatory function is also known to be regulated by the tyrosine 
phosphatases SYP, SHP1 and PTP-1B. Interestingly, protein levels of SYP and 
SHP1 were reduced, respectively, by 3- and 2-fold in Prep1i/i mice livers and 
more moderately in Prep1i/+ mice (Figure 11a).  This reduction appeared, at least 
in part, transcriptional, in fact, consistently with this hypotesis, SYP and SHP1 
mRNA levels were also decreased in the Prep1i/+ and Prep1i/i mice (Figure 11b). 
Surprisingly, PTP-1B levels did not change in the Prep1 hypomorphic animals 
(Figure 11a, b). 
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Figure 11. Protein and mRNA levels of SYP, PTP1-B and SHP1 in hepatic tissue of Prep1 
hypomorphic mice. SYP, PTP1-B and SHP1 tyrosine phosphatases protein expression was 
measured by western blot in hepatic tissues from hypomorphic and control mice using anti- SYP, 
PTP-1B and SHP1 antibodies.  Each bar represents the mean ± SD of duplicate determinations in 
10 mice/group. Asterisks denote statistically significant differences (**, p < 0.01; ***, p < 0.001) 
(a). The abundance of mRNAs of SYP, PTP-1B and SHP1 genes was determined by real-time RT-
PCR analysis of total RNA isolated from liver tissue of the hypomorphic and control mice, using 
beta-actin as internal standard. Each bar represents the mean ± SD of four independent experiments 
performed in 6 mice/genotype (b). 
 
The tyrosine phosphatases PTP-1B, SYP, and SHP1 play a fundamental role in the 
insulin-dependent liver glucoregulatory function. They are known to negatively 
modulate insulin action on liver glucose metabolism through tyrosine 
dephosphorylation of the insulin receptor and/or insulin receptor substrates. The 
balance in the level of activity of these individual phosphatases represents an 
important determinant of normal liver glucoregulation. How, at the physiological 
and molecular levels, this balance is maintained has been only partially elucidated. 
Prep1 might be a pivotal molecule in the regulation of these phosphatases and it 
could be a novel candidate in their transcriptional modulation. 
To further examine Prep1 action on early tyrosine phosphorylation in the insulin 
signaling cascade and on the regulation of tyrosine phosphatases, I have transiently 
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transfected a Prep1 cDNA in the HepG2 hepatoma cells, which represent a good 
model of liver cells. As shown in figure 12a, the transfection almost completely 
prevented insulin-induced tyrosine phosphorylation of the insulin receptor as well 
as that of IRS-1 and IRS-2. No change was evidenced in the abundance of any of 
these proteins. Furthermore, Prep1 transfection up-regulated SYP and SHP1 
expression both at the mRNA and the protein levels but elicited no action on that 
of PTP-1B (figure 12c, d). 
The effects of Prep1 on gene regulation is tightly dependent on many interactors 
which can recruit it in different transcription networks and modulate the target of 
its transcription activity. Since one of the main partners of Prep1 is Pbx1, I focused 
my attention on the transcription complex Prep1-Pbx1 as a possible regulator of 
the transcription of the SYP and SHP1 genes. To validate this hypothesis, I 
transfected HepG2 cells with cDNAs of Pbx1 and Prep1HR1 This mutant contains 
one point mutation in the domain HR1 which is fundamental for the interaction 
between Prep1 and Pbx1, resulting in an abolishment of the recruitment and 
function of the transcription complex. Interestingly, the overexpression of a Pbx1 
cDNA in HepG2 cells mimicked Prep1 effects on insulin-stimulated tyrosine 
phosphorylation of the insulin receptor kinase and IRS-1/2 (figure 12b), as well as 
the effects of Prep1 on SYP and SHP1 gene and protein expression (figure 12c, d). 
More importantly, Prep1HR1 mutant was unable to exert the biological effects 
exerted by the overexpression of the WT protein and Pbx1 (Figure 12a,c,d). 
Moreover, transfection of the Prep1 cDNA, but not that of the Prep1HR1 mutant, 
abolished insulin-induced glycogen accumulation in the HepG2 cells (figure 13). 
As in the case of the insulin signal activation, the effect of Prep1 was mimicked by 
Pbx1 overexpression. 
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Figure 12. Effect of Prep1, Pbx1 and Prep1HR1 cDNAs transfection on insulin signaling and 
tyrosine phosphatases expression. HepG2 cells were transiently transfected with the Prep1, Pbx1 
and Prep1HR1 mutant cDNAs and exposed to 100 nM insulin for 5 minutes. Afterwards, cells were 
solubilized and the lysates were immunoprecipitated with anti  IR, IRS1 or IRS2 antibodies 
followed by blotting with pY, IR, IRS1 or IRS2 antibodies. The total lysates were blotted with anti 
Prep1, Pbx1 or actin antibodies. Bands were revealed by ECL and autoradiography. The 
autoradiograph shown is representative of four independent experiments (a,b). Lysates from 
HepG2 cells transiently overexpressing were subjected to western blot analysis  blotted with anti 
SYP, PTP-1B and SHP1 antibodies. Each bar represents the mean ± SD of duplicate determinations 
in four independent experiments. (c). The levels of mRNAs encoding SYP, PTP-1B and SHP1 was 
quantified by real-time RT-PCR analysis, using beta-actin as internal standard. Bars represent the 
mean ± SD of four independent experiments (d). Asterisks denote statistically significant 
differences (**, p < 0.01; ***, p < 0.001) (c, d). 
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Figure 13. Insulin-induced glycogen storage in HepG2 transfected with Prep1, Pbx1 and 
Prep1HR1 cDNAs. HepG2 cells were transiently transfected with the Prep1, Pbx1, Prep1HR1 
cDNAs and to 100 nM insulin 14-16 hours, glycogen content was assayed as described under 
“materials and methods” . Bars represent mean values ± SD of determinations in four independent 
experiments, each in duplicate. Asterisks denote statistically significant differences (**, p < 0.01) 
 
These results led me to postulate an important role of Pbx1 in enabling Prep1 
control of insulin action in liver cells as well as in the regulation of SYP and SHP1 
expression.  
Next, I studied the single contribution of SYP and SHP1 in Prep1/Pbx1-regulation 
of insulin signaling in liver by stably transfecting a Prep1 full-lenght cDNA in the 
HepG2 cells. Several clones were obtained and three of those, expressing 
increasing levels of Prep1 were selected and further characterized (figure 14a). 
The HepG2Prep1c clone overexpressed Prep1 by 5-fold compared to wild type 
HepG2 cells and featured a 4- and 3-fold increased expression of SYP and SHP1, 
respectively (figure 14b). Increased SYP and SHP1 levels were also measured in 
the HepG2Prep1a and HepG2Prep1b cells and directly paralleled the level of Prep1 
overexpression achieved in each clone (data not shown). Transient transfection of 
the HepG2Prep1c cells with phosphorothioate antisense oligonucleotides specific for 
SYP (SYP-AS) caused a > 65% reduction in SYP levels but elicited almost no 
change in insulin-stimulated phosphorylation of the insulin receptor, suggesting no 
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change in insulin action in these cells (figure 14c). At variance, treatment with 
SHP1 antisense oligonucleotides (SHP1-AS) silenced SHP1 expression by only 
50% but increased insulin receptor tyrosine phosphorylation by almost 3-fold 
(figure 14d). Indeed, the impaired insulin-dependent accumulation of glycogen 
observed in liver cells overexpressing Prep1 was unaffected by SYP silencing but 
was rescued by the SHP1 AS (figure 15). Thus, regulation of the SHP1 gene 
function appeared to represent a mechanism relevant to Prep1 control on insulin 
signaling and action in the hepatocyte. However, I cannot exclude the fact that 
there could be a major role for SYP in regulating insulin signaling in a different 
tissue or in different environmental conditions.  
 
 
 
Figure 14. Effect of SYP and SHP1 silencing in HePG2 cells stably transfected with Prep1 
cDNA. HepG2 cells were stably transfected with the Prep1 cDNA. Clones HepG2Prep1A, 
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HepG2Prep1B, HepG2Prep1C were subjected to western blot analysis, blotted with Prep1 
antibodies, and compared with control cells (HepG2) (a). Cell lysates from HepG2 or 
HepG2Prep1c cells were blotted with anti SYP, SHP1 and  actin antibodies. HepG2 and 
HepG2Prep1c cells were transfected with SYP (SYP-AS) (c) or SHP1 (SHP1-AS) (d) specific 
phosphorothioate antisense oligonucleotides, then stimulated with 100nM insulin for 5 minutes and 
the insulin receptor was immunoprecipitated with specific antibodies and followed by blotting with 
either pY and IR antibodies. For control, total lysates were blotted with anti SYP (c) or SHP1 (d) 
and actin antibodies. The autoradiographs shown are representative of three independent 
experiments. 
 
 
Figure 15. Insulin-induced glycogen accumulation in HepG2 cells stably overexpressing 
Prep1 interfered with SYP and SHP1 antisense oligonucleotides. Cells were stimulated with 
100nM insulin for 14-16 hours, afterwards, glycogen content was assayed as described under 
“Materials and Methods”. Bars represent mean values ± SD of determinations in four independent 
experiments, each in duplicate. Asterisks denote statistically significant differences (**, p < 0.01). 
 
Understanding how Prep1-Pbx1 might regulate the expression of SHP1 gene is a 
critical point to better define the action of this transcription complex in modulating 
insulin action in liver cells. I therefore examined the further possibility that the 
transcription complex Prep1-Pbx1 might directly regulates SHP1 gene 
transcription. To address this hypothesis, I performed a bioinformatic analysis of  
4000 base pairs region upstream the ATG codon of SHP1 gene searching potential 
binding sites for the Prep1 and Pbx1 complex. This analysis revealed the presence 
of  at least 7 potential binding sites resumed in the table 2. Interestingly, these 
sequences were arranged in 3 clusters, indicated as SHP1 n.1, n.2, n.3 mapping 
from -2489 to -2139bp, -2113 to -1778bp, -1680 to -1350bp respectively from the 
ATG codon (figure 16). As negative control, I also analyzed the sequence 
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upstream PTP-1B gene whose expression was not modified by Prep1 and, 
interestingly,  this sequence showed only 2 binding sites from -3895 to 3879bp and 
-1004 to 988bp indicated as PTP-1B n.1 and n.2.  
 
 
 
Table 2. Bioinformatic analysis of  4000 bp upstream the ATG codon of SHP1 and PTP-1B 
genes. Mouse sequences of 4000 bp uspstream the ATG codon of SHP1 and PTP-1B genes were 
analyzed through Matinspector bioinformatic software. The table indicates the potential binding 
sites for Prep1-Pbx1 complex which showed a score of 1 (range 0-1). 
 
To validate the regions putatively bound by Prep1 and Pbx1 complex I performed 
chromatin immunoprecipitation (ChIP) and re-chromatin immunoprecipitation (re-
ChIP) experiments in NmuLi mouse liver cell line. ChIP experiments confirmed 
that sites from -2489 to -2139bp and -2113 to -1778bp (SHP1 n.1 and n.2) were 
consistently bound by Prep1, importantly, re-ChIP assays revealed that Pbx1 was 
simultaneously present only at position -2113 to -1778bp (SHP1 n.2) (figure 16). 
Consistent with the lack of Prep1 regulation, no Prep1/Pbx1 complex was detected 
at any of the potential binding sites identified in the PTP-1B regulatory region by 
sequence analysis (figure 16). The results obtained with ChIP and re-ChIP 
procedures confirmed the binding of the Prep1-Pbx1 complex on the region -2113 
to -1778bp upstream the ATG codon of SHP1 gene.  
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Figure 16. ChIP and re-ChIP on the sequences upstream ATG codon of SHP1 and PTP-1B 
genes. Soluble chromatin was prepared from NMuLi mouse liver cells and immunoprecipitated 
with Prep1 antibodies. Total (input) and immunoprecipitated DNAs were amplified  by PCR 
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analysis using primer pairs covering SHP1 sequences n.1, n.2, n.3 (a) and PTP-1B sequences n.1, 
n.2 (b). Re-ChIP assay (a) with Pbx1 antibodies was performed as described in “Material and 
Methods”. 
 
To investigate whether this region (SHP1 n.2) might have a functional activity 
luciferase assays were performed. In particular, the region SHP1 n.2 was cloned 
into PGL3promoter vector plasmid upstream the luciferase reporter gene and 
SV40 promoter sequence. The construct was then co-transfected in HeLa cells 
together with the Prep1, Pbx1 or both plasmid cDNAs and luciferase activity was 
measured (figure). Prep1 and Pbx1 increased the SHP1 reporter gene activity, 
respectively, by 7.1 and 6-fold. Furthermore, simultneous co-transfection of the 
two plasmids caused an almost 30-fold induction, indicating SHP1 transcriptional 
regulation by the Prep1-Pbx1 complex (figure 17). 
 
 
 
Figure 17. Luciferase activity of SHP1 -2113 to -1778bp region. HeLa cells were transfected 
with 2 g of the SHP1 enhancer-luciferase construct alone or in combination with  Prep1 (2 g), 
Pbx1 (2 g) or both the cDNA plasmids. Luciferase activity was assayed  and normalized as 
described in Material and Methods. Bars represent mean values ± SD of determinations in four 
independent experiments. Asterisks denote statistically significant differences (**, p < 0.01; ***, p 
< 0.001). 
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These results indicated that the transcription complex Prep1-Pbx1 may directly 
bind consensus sequences upstream the ATG codon of SHP1 gene and directly up-
regulate its promoter activity. In particular, since the plasmid which I have used to 
perform the luciferase assays already have a promoter sequence (SV40), the results 
indicated that the sequence SHP1 n.2 which I have cloned upstream this promoter 
has an enhancer activity in response to Prep1-Pbx1 complex. However, if the 
region SHP1 n.2 also has a promoter activity is currently under investigation, but 
the relatively large distance from the ATG codon (-2113 base pairs) makes 
unfavourable this hypothesis. 
Additional data in my possess collected by ChIP procedures and luciferase assays 
indicated that SYP tyrosine phosphatases may also be directly regulated by Prep1-
Pbx1 complex but the results obtained after the silencing of the single 
phosphatases (figure 15) induced me to focus my attention on SHP1 and its 
transcriptional regulation. How and, above all, in which tissue SYP may contribute 
in Prep1-dependent insulin action is actually another field of my research activity. 
The quest of tyrosine phosphatases and their action is always been controversial 
and debated. In this work I have identified a novel transcription complex which 
may directly be involved in the regulation of at least 2 tyrosine phosphatases in 
liver cells and in mouse liver which may modulate insulin action.  
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CONCLUSIONS 
 
Insulin-dependent liver glucoregulatory function plays a central role in glucose 
metabolism and it is known to be modulated by a number of different mechanisms. 
In the present work I have focused my attention on Prep1 action on hepatic 
glucose metabolism. I have described that Prep1 deficiency in animal models 
improves insulin signaling in liver increasing glycogen storage and reducing 
glucose output. These effects are paralleled by a significant reduction of 
expression of SYP and SHP1 tyrosine phosphatases. In particular, expression of 
SHP1 in animal and cellular models negatively correlates with insulin signaling. 
This evidence led me to focus the research activity on the transcriptional 
regulation of SHP1 by the Prep1-Pbx1 complex. In this context, I have shown that 
Prep1-Pbx1 may enhance SHP1 gene transcription by acting on regulatory 
sequences upstream the ATG codon.  
In conclusion, these findings have contributed to underline the link between the 
TALE proteins and insulin-resistance and/or diabetes and to clarify the role of 
tyrosine phosphatases on hepatic insulin-resistance.  
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Phorbol Esters Induce Intracellular Accumulation of the
Anti-apoptotic Protein PED/PEA-15 by Preventing
Ubiquitinylation and Proteasomal Degradation*
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Phosphoprotein enriched in diabetes/phosphoprotein en-
riched in astrocytes (PED/PEA)-15 is an anti-apoptotic protein
whose expression is increased in several cancer cells and follow-
ing experimental skin carcinogenesis. Exposure of untrans-
fected C5N keratinocytes and transfected HEK293 cells to
phorbol esters (12-O-tetradecanoylphorbol-13-acetate (TPA))
increased PED/PEA-15 cellular content and enhanced its
phosphorylation at serine 116 in a time-dependent fashion.
Ser-116 3 Gly (PEDS116G) but not Ser-1043 Gly (PEDS104G)
substitution almost completely abolished TPA regulation of
PED/PEA-15 expression. TPA effect was also prevented by anti-
sense inhibition of protein kinase C (PKC)- and by the expres-
sion of a dominant-negative PKC- mutant cDNA in HEK293
cells. Similar to long term TPA treatment, overexpression of
wild-type PKC- increased cellular content and phosphoryla-
tion of WT-PED/PEA-15 and PEDS104G but not of PEDS116G.
These events were accompanied by the activation of Ca2-cal-
modulin kinase (CaMK) II and prevented by the CaMK blocker,
KN-93. At variance, the proteasome inhibitor lactacystin mim-
icked TPA action on PED/PEA-15 intracellular accumulation
and reverted the effects of PKC- and CaMK inhibition. More-
over, we show that PED/PEA-15 bound ubiquitin in intact cells.
PED/PEA-15 ubiquitinylation was reduced by TPA and PKC-
overexpression and increased by KN-93 and PKC- block. Fur-
thermore, in HEK293 cells expressing PEDS116G, TPA failed to
prevent ubiquitin-dependent degradation of the protein.
Accordingly, in the same cells, TPA-mediated protection from
apoptosis was blunted. Taken together, our results indicate that
TPA increasesPED/PEA-15 expression at thepost-translational
level by inducing phosphorylation at serine 116 and preventing
ubiquitinylation and proteosomal degradation.
Cancer cells feature both excessive proliferation and aban-
donment of the ability to die (1, 2). Thus, alterations of genes
involved in the control of apoptosis have been implicated in a
number of human malignancies. In certain lymphomas, for
example, cell death is blocked by excessive production of the
anti-apoptotic factor Bcl-2 (2). Similarly, some tumors prevent
apoptosis by up-regulating the expression of anti-apoptotic
death effector domain (DED)2-containing proteins, which, in
turn, inhibit Fas from conveying signals to the deathmachinery
(3).
Phosphoprotein enriched in diabetes/phosphoprotein
enriched in astrocytes (PED/PEA)-15 is a DED-containing pro-
tein originally identified in astrocytes as a protein kinase C
(PKC) substrate (4–6) and found overexpressed in insulin tar-
get tissues of patients with type 2 diabetes (7). Raised PED/
PEA-15 levels have also been detected in several human tumor
cell lines (7–9). A growing body of evidence indicates that
increased PED/PEA-15 expression may provide a mechanism
to escape cell death upon a number of pro-apoptotic stimuli
(10–14).Moreover, in transgenicmice, overexpression of PED/
PEA-15 enhances the susceptibility to develop experimentally
induced skin tumors (15). The molecular mechanism of PED/
PEA-15 anti-apoptotic action has been extensively investi-
gated. In several cell types, PED/PEA-15 blocks Fas- and tumor
necrosis factor--induced apoptosis by competing with its
DEDwith the interaction between FADD and caspase 8 (10). In
addition, in several cell lines of human glioma, PED/PEA-15
inhibits tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-induced apoptosis, thereby generating resist-
ance to this anti-neoplastic agent (9). At variance with other
anti-apoptotic proteins inhibiting caspase 8 activation via
FADD trapping (3), PED/PEA-15 overexpression also prevents
apoptosis induced by growth factors deprivation, UV exposure,
and osmotic stimuli (11, 13).
Besides the anti-apoptotic function, a role for PED/PEA-15
in restraining cell proliferation has been proposed (16–20). It
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has been described that PED/PEA-15 directly binds extracellu-
lar signal-regulated kinase 2 (ERK2) and RSK2 and prevents
their nuclear translocation and transduction of biological
effects (16–19). Together with the anti-apoptotic effect, this
action may expand cellular senescence (20).
PED/PEA-15 is a phosphorylated protein (4, 5). It has
recently been shown that PED/PEA-15 phosphorylation at spe-
cific sites controls the ability of the protein to form complexes
with specific intracellular interactors (21). PED/PEA-15 serine
phosphorylation has also been shown to enhance protein sta-
bility (22). Several kinases were evidenced to phosphorylate
PED/PEA-15 at specific serines. Ser-104 represents the main
target for PKC phosphorylation (4, 5, 23), whereas Ser-116 has
been shown to be a target site for both Ca2-calmodulin kinase
(CaMK) II (23) and protein kinase B (PKB)/Akt (22). However,
the precise function of these phosphorylation sites in control-
ling PED/PEA-15 expression is currently unknown. Recent evi-
dence indicates that abnormal accumulation of PED/PEA-15may
lead to derangement of cell growth andmetabolism (15, 24, 25).
In this study, we have shown that phorbol esters, which are
tumor promoters and inhibitors of insulin action, up-regulate
PED/PEA-15 expression by inhibiting its ubiquitinylation and
proteasomal targeting. This effect involves activation of
CaMKII and subsequent phosphorylation of PED/PEA-15 at
Ser-116. PKC- activity is required for phorbol ester-induced
activation of CaMKII and for the regulation of PED/PEA-15
degradation.
EXPERIMENTAL PROCEDURES
Materials—Media, sera, and antibiotics for cell culture and
the Lipofectamine reagent were purchased from Invitrogen
(Paisley, UK). Rabbit polyclonal PKC-, PKC-, PKC-, PKC-,
and phospho-PKC antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA). PED/PEA-15, p-Ser-104PED, and
p-Ser-116PEDand antibodies have been previously reported (7,
22). Mouse monoclonal polyubiquitinylated protein antibodies
(FK1) were from Biomol International. Mouse monoclonal HA
antibody were from Roche Applied Science. Phosphorothioate
PKC-, PKC-, PKC-, PKC- antisense and scrambled con-
trol oligonucleotides have been previously described (26–28)
and were synthesized by PRIMM (Milan, Italy). PKC- wild-
type and dominant-negative constructs were kindly provided
byDr.M. S.Marber (St. ThomasHospital, London,UK) andDr.
S.Gutkind (NCI, National Institutes of Health, Bethesda, MD),
respectively. SDS-PAGE reagents were purchased from Bio-
Rad. Western blotting and ECL reagents and radiochemicals
were from Amersham Biosciences. All other reagents were
from Sigma.
Plasmid Preparation, Cell Culture, and Transfection—The
PEDS104G andPEDS116Gmutant cDNAswere prepared by using
pcDNAIIIPEDY1 cDNA (pcDNAIII containing His6-Myc-
tagged PED/PEA-15) as template with the site-directed
mutagenesis kit by Promega according to the manufacturer’s
instructions. Stable expression of the mutants and wild-type
PEDY1 cDNAs in HEK293 cells (293PEDY1) was achieved as
reported in Condorelli et al. (11). The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum, 100 IU of penicillin/ml, 100 IU of
streptomycin/ml, and 2% L-glutamine in a humidified CO2
incubator. Transient transfection of phosphorothioate oligo-
nucleotides and plasmid DNA in HEK293 cells was accom-
plished by using the Lipofectamine method according to the
manufacturer’s instructions. Briefly, the cells were cultured in
60-mm-diameter dishes and incubated for 24 h in serum-free
DMEM supplemented with 3 g of cDNA and 15 l of Lipo-
fectamine reagent. An equal volume of DMEM supplemented
with 20% fetal calf serum was then added for 5 h followed by
replacement with DMEM supplemented with 10% serum for
24 h before the assays.
Western Blot Analysis—ForWestern blotting, cells were sol-
ubilized in lysis buffer (50mMHEPES (pH 7.5), 150mMNaCl, 4
mM EDTA, 10 mM Na4PO7, 2 mM Na3VO4, 100 mM NaF, 10%
glycerol, 1%TritonX-100, 1mMphenylmethylsulfonyl fluoride,
100mg of aprotinin/ml, 1mM leupeptin) for 60min at 4 °C. Cell
lysates were clarified at 5,000  g for 15 min. Solubilized pro-
teins were then separated by SDS-PAGE and transferred onto
0.45-m-pore size Immobilon-P membranes (Millipore, Bed-
ford, MA). Upon incubation with the primary (PED, etc.) anti-
body and secondary antibodies, immunoreactive bands were
detected by ECL according to the manufacturer’s instructions.
Real-time RT-PCR Analysis—Total cellular RNA was iso-
lated from C5N cells by the use of RNeasy kit (Qiagen) accord-
ing to the manufacturer’s instructions. For real-time RT-
PCR analysis, 1 g of cell RNA was reverse-transcribed using
SuperScript II reverse transcriptase (Invitrogen). PCR reaction
mixes were analyzed using SYBRGreenmix (Invitrogen). Reac-
tions were performed using Platinum SYBRGreen quantitative
PCR Super-UDG using an iCycler IQmulticolor real-time PCR
detection system (Bio-Rad). All reactions were performed in
triplicate, and -actin was used as an internal standard. Primer
sequences used were as follows: PED/PEA-15, forward, 5-
TTCCCGCTGTTCCCTTAGG-3, and PED/PEA-15, reverse
5-TCTGGCTCATCCGCATCC-3.
Immunoprecipitation of PED/PEA-15—Cells grown in
100-mmPetri disheswere treated as indicated andwashed once
with ice-cold PBS and solubilized in lysis buffer for 2 h at 4 °C.
Then, lysates were clarified by centrifugation at 5,000 g for 20
min. 500 g of protein lysates was immunoprecipitated with
Myc or PED antibodies for 16 h. The precipitates were incu-
bated with protein G-Sepharose beads at 4 °C for 1 h with shak-
ing. Beads were precipitated by centrifugation at 1,000 g for 5
min at 4 °C and washed five times with ice-cold washing buffer.
After the final wash, the pellets were resuspended in 30l of 1
SDS electrophoresis buffer and heated to 95 °C for 5 min prior
to protein separation by 15% SDS-PAGE.Western blot analysis
was performed as described above.
Purification of Ubiquitin-PED/PEA-15 Conjugates—Cellular
ubiquitinylation assay was performed as described by Musti et
al. (29). Briefly, 24 h after transfection, cells expressing His-
tagged-PED/PEA-15 (PED/PEA-15Y1) and HA-ubiquitin were
harvested in 2ml of 6M guanidium-HCl, 0.1 MNa2HPO4/NaH2
PO4 (pH 8) plus 5 mM imidazole/100-mm dish and sonicated
with a Branson micro-tipped sonifier for 30 s to reduce viscos-
ity. Lysatesweremixed on a rotatorwith 0.2ml (settled volume)
of Ni2-nitrilotriacetic acid-agarose (Qiagen) for 4 h at room
temperature. The slurry was applied to a Bio-Rad Econo-Col-
Regulation of PED/PEA-15 Ubiquitinylation
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umn.The columnwas successivelywashedwith the following: 1
ml of 6 M guanidium-HCl, 0.1 MNa2HPO4, NaH2 PO4 (pH 8); 2
ml of 6 M guanidium-HCl, 0.1 MNa2HPO4, NaH2 PO4 (pH 5.8);
1 ml of 6 M guanidium-HCl, 0.1 M
Na2 HPO4, NaH2 PO4 (pH 8); 2 ml
of (6 M guanidium-HCl, 0.1 M Na2
HPO4, NaH2 PO4 (pH 8), protein
buffer) 1:1; 2 ml of (6 M guanidium-
HCl, 0.1 M Na2 HPO4, NaH2 PO4
(pH 8), protein buffer) 1:3; 2 ml of
protein buffer; 1ml of protein buffer
plus 10 mM imidazole. Elution was
performed with 1 ml of protein
buffer plus 200 mM imidazole. Pro-
tein buffer is 50 mM Na2 HPO4,
NaH2 PO4 (pH 8), 100 mMKCl, 20%
glycerol, and 0.2% Nonidet P-40.
The eluate was trichloroacetic acid-
precipitated for further analysis by
Western blot with HA antibody.
Cell Death Analysis by Flow
Cytometry—Cells were harvested
and suspended in the sample buffer
(PBS 2% fetal bovine serum; PBS
0.1% bovine serum albumin) and
washed and resuspended in 0.3 ml
of PBS. After adding 0.7 ml of cold
absolute ethanol, cells were fixed for
at least 2 h at20 °C, washed twice,
and resuspended in 0.4 ml of PBS.
Samples were then incubated with
20 l of propidium iodide (1 mg/ml
stock solution) and 2 l of RNaseA
(500 mg/ml stock solution) in dark
for 30 min at room temperature.
Samples were stored at 4 °C until
analyzed by flow cytometry.
RESULTS
Regulation of PED/PEA-15 Pro-
tein Expression by Phorbol Esters—
The expression of PED/PEA-15 is up-regulated by phorbol
myristate acetate (TPA) in the mouse skin upon experimental
carcinogenesis as well as in different human tumors (7–9, 15).
To investigate the molecular mechanisms regulating PED/
PEA-15 expression, HEK-293 cells, stably transfected with
PED/PEA-15 cDNA (293PEDY1), were incubated with serum-
free medium in the absence or in the presence of 1 M TPA.
Treatment of 293PEDY1 cells with TPA increased PED/PEA-15
levels in a time-dependentmanner (Fig. 1A). Serumdeprivation
alone was sufficient to reduce PED/PEA-15 protein levels by
3-fold (Fig. 1B). This decrease was totally reverted by the
simultaneous exposure to TPA. Pretreatment of the cells with
the protein synthesis inhibitor cycloheximide (40 g/ml)
reduced TPA effect by only 25% (Fig. 1B, left panel). Similar
results were also obtained by evaluating the levels of PED/
PEA-15 in C5N keratinocytes, expressing only the endogenous
compendium of the protein (Fig. 1B, right panel). Moreover, as
shown in Fig. 2, PED/PEA-15 mRNA was also increased in
untransfectedC5N cells following 6 and 20 h of TPA treatment.
Thus, TPA up-regulates PED/PEA-15 mRNA and protein
FIGURE 1. TPA effect on PED/PEA-15 protein expression. A, 293PEDY1 cells were serum-starved for 40 h and
stimulatedwith1MTPAforthe indicatedtimes.Cell lysateswereseparatedonSDS-PAGEandimmunoblottedwith
PEDAb. Filters have been analyzed by laser densitometry. The error bars represent themean S.D. of the densito-
metric analyses. B, 293PEDY1 cells (left panel) and C5N keratinocytes (right panel) were serum-starved, as indicated,
and treatedwith 1M TPA for 20 h in the absence or in the presence of 40g/ml cycloheximide (CXM). Cell lysates
were then analyzed by PED immunoblot, and the results were quantitated by laser densitometry. The autoradio-
graphs shown are representative of three (A) and four (B) independent experiments.
FIGURE 2. TPA effect on PED/PEA-15mRNA levels. The abundance of mRNAs
for PED/PEA-15 was determined by real-time RT-PCR analysis of total RNA iso-
lated fromC5Ncells following treatmentwith TPA (1M) for the indicated times,
using -actin as internal standard. The mRNA levels in TPA-stimulated cells are
relative to those in control cells. Each error bar represents themean S.D. of four
independentexperiments ineachofwhich reactionswereperformed in triplicate.
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expression. However, TPA regulation is, at least in part, inde-
pendent of protein synthesis.
Regulation of PED/PEA-15 Expression by Serine Phosphor-
ylation—It has been shown that PED/PEA-15 expression is
tightly regulated by its phosphorylation state (22).We therefore
investigated whether TPA could induce PED/PEA-15 phos-
phorylation. To this end, protein extracts of TPA-stimulated
293PEDY1 and C5N cells were immunoblotted with antibodies
against the phosphorylated forms of Ser-104 and Ser-116 (Fig.
3A). In 293PEDY1 cells, Ser-104 phosphorylation increased
within the initial 30 min of TPA exposure, declining thereafter.
At variance, Ser-116 phosphorylation was barely detectable at
30 min and progressively raised for up to 20 h after TPA expo-
sure. Similarly, inC5Nkeratinocytes, 20 h of TPA treatment led
to a significant increase of Ser-116 phosphorylation, with
almost undetectable changes of Ser-
104 phosphorylation (Fig. 3A).
To assess the relevance of those
phosphorylation sites, PED/PEA-15
mutants bearing Ser-104 3 Gly
(PEDS104G) or Ser-116 3 Gly
(PEDS116G) substitutions were
transfected in HEK293 cells. TPA
treatment increased the levels of the
wild-type PED/PEA-15 (PEDWT)
and of PEDS104G by about 4-fold. At
variance, PEDS116G expression was
increased by only 2-fold upon TPA
exposure (Fig. 3B), suggesting that
phosphorylation of Ser-116 is
required for TPA regulation of
PED/PEA-15 expression.
PKC Regulation of PED/PEA-15
Expression—To identify the kinase
responsible for the regulation of
PED/PEA-15 expression, 293PEDY1
cells were treated with specific
phosphorothioate antisense oligo-
nucleotides (ASO) toward individ-
ual PKC isoforms (Fig. 4). Based on
Western blot experiments, ASO for
PKC-, -, and - did not signifi-
cantly affect PED/PEA-15 expres-
sion levels when compared with
scrambled (SO) oligonucleotide
controls. The expression of the tar-
geted PKC isoform was selectively
reduced by50%, however. At vari-
ance, ASO-mediated silencing of
PKC- expression (PKC-ASO) was
accompanied by a significant 70%
decrease of PED/PEA-15 levels (Fig.
4). A scrambled oligonucleotide
(PKC-SO) did not induce any
detectable change (Fig. 4). A reduc-
tion of PED/PEA-15 expression was
also observed when 293PEDY1 cells
were transfected with a dominant-
negative (DN) PKC- mutant or with PKC-ASO and stimu-
lated with TPA for 20 h (Fig. 5A). CaMKII and Akt/PKB have
been shown to directly phosphorylate PED/PEA-15 at Ser-116
(22, 23). Interestingly, a 75% decrease of PED/PEA-15 expres-
sion was also detected in 293PEDY1 cells treated with the CaMK
inhibitor, KN-93 (Fig. 5A). Similarly, in C5N keratinocytes,
TPA-induced up-regulation of PED/PEA-15 protein expres-
sion was reduced by about 70% by KN-93 treatment (Fig. 5B).
Next, we investigated whether TPA could regulate CaMKII
activity in 293PEDY1 and in C5N cells. In this regard, CaMKII
phosphorylation (Fig. 6A) was induced by TPA and well corre-
lated with increased PED/PEA-15 expression levels and Ser-
116 phosphorylation in 293PEDY1 cells (Figs. 1A and 3A). Con-
sistently, 20 h of TPA treatment of C5N cells was accompanied
by a 2.5-fold increase ofCaMKII phosphorylation (Fig. 6A). The
FIGURE 3.Regulationof PED/PEA-15phosphorylation levels by TPA.A, 293PEDY1 andC5N cellswere serum-
starved and stimulated with 1 M TPA for the indicated times. Cell lysates were separated on SDS-PAGE and
immunoblotted either with p-PEDS104 Ab or with p-PEDS116 Ab. Each filter has been reprobed with PED Ab
for the normalization. The results have been analyzed by laser densitometry, and the error bars represent the
mean S.D. of the densitometric analyses obtained in four duplicate experiments. B, HEK293 cells have been
transfected with PEDWT, PEDS104G, and 293PEDS116G, as indicated. Next, cells were serum-starved and stimu-
latedwith 1MTPA for 20 h. Cell lysateswere separated on SDS-PAGE and immunoblottedwith PEDAb. Filters
have been analyzed by laser densitometry. The autoradiograph shown is representative of five independent
experiments. The error bars represent the mean S.D. of the densitometric analysis.
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expression of DN-PKC- and the treatment of 293PEDY1 cells
with PKC-ASO reduced by about 65% TPA-induced CaMKII
activation (Fig. 6B). Conversely, overexpression of the wild-
type PKC- led to3-fold increase of CaMKII activity. At vari-
ance, Akt/PKB activity was not induced following 20 h of TPA
treatment of both 293PEDY1 and C5N cells (Fig. 6C).
Moreover, TPA treatment and PKC- overexpression
increased by 5-fold the phosphorylation of PED/PEA-15 at
Ser-116. Pretreatment of 293PEDY1 cells with KN-93 almost
completely reverted both TPA- and PKC--induced phospho-
rylation of PED/PEA-15 (Fig. 7A). TPA-induced Ser-116 phos-
phorylation was also reduced by KN-93 in C5N keratinocytes.
Consistent results were obtained in transiently transfected
HEK293 cells by analyzing the expression of PEDWT and
PEDS104G but not of PEDS116G (Fig. 7B). Indeed, PKC--medi-
ated changes of PEDWT and PEDS104G were prevented by
KN-93, which, instead, had no effect on the regulation of
PEDS116G expression.
Regulation of PED/PEA-15 Ubiquitinylation—We hypothe-
sized that PED/PEA-15 protein accumulation within the cell
was due to decreased degradation. To investigate the mecha-
nisms regulating PED/PEA-15 degradation, 293PEDY1 cells
were treated with the proteasomal inhibitor lactacystin. Lacta-
cystin (30 M) inhibited the degradation of PED/PEA-15
induced by serum deprivation by 70% and almost completely
reverted the effect of the PKC-ASO (Fig. 8A). Lactacystin
treatment also prevented PED/PEA-15 degradation induced by
KN-93 in the 293PEDY1 cells (data not shown). In addition, lac-
tacystin, at variance with TPA, increased the expression of
PEDS116G at a similar extent as PEDWT (Fig. 8B), suggesting that
PED/PEA-15 phosphorylation at the Ser-116 was required to
escape degradation. Following lactacystin treatment of the
untransfected C5N cells, PED/PEA-15 protein levels were also
increased by 2.5- and 3-fold, respectively, in the absence or in
the presence of TPA (Fig. 8B). In both cases, the incubation
with KN-93 did not significantly reduce lactacystin effect on
PED/PEA-15 protein levels. Thus, CaMK block was overcome
by proteasome inhibitors.
These data were consistent with the hypothesis that PED/
PEA-15 is largely degraded within the proteasomal compart-
ment. Proteasome-targeted proteins are usually ubiquitiny-
lated (30). His-tagged PED/PEA-15 and HA-tagged ubiquitin
have been transfected, alone or in combination, in HEK293
cells, and PED/PEA-15-bound ubiquitin was detected byWest-
ern blot with HA antibodies (Fig. 9A). A typical smear was
observed in cells co-transfected with both constructs, indicat-
ing that PED/PEA-15 is a ubiquitinylated protein (Fig. 9A).
FIGURE 4. Regulation of PED/PEA-15 expression levels by PKC isoforms.
293PEDY1 cellswere treatedwithphosphorothioate antisense (ASO) and sense
(SO) oligonucleotides (3 g/ml) directed against PKC-, -, -, and -. Cell
lysates were then analyzed by PED immunoblot, and the results were quan-
titated by laser densitometry. The autoradiograph shown is representative of
five independent experiments. The error bars represent the mean  S.D. of
the densitometric analysis.
FIGURE 5. Regulation of PED/PEA-15 expression levels by PKC and
CaMK. 293PEDY1 (A) and C5N (B) cells were serum-starved and treated with 1
M TPA or with 10 M KN-93 for 20 h in the absence or in the presence of
PKC-ASO and PKC-SO or DN-PKC, as indicated. Cell lysates were then ana-
lyzedbyPKC- (upper part) or PEDAb (lower part) immunoblot, and the results
were quantitatedby laser densitometry. The autoradiographs shownare rep-
resentative of four (A) and three (B) independent experiments. The error bars
represent the mean S.D. of the densitometric analyses.
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Next, 293PEDY1 cells were incubated in serum-freemedium and
treated with TPA for 20 h or transfected with wild-type PKC-.
PED/PEA-15 immunoprecipitates were then blotted with FK1
antibodies, which recognize polyubiquitinylated proteins.
Interestingly, PED/PEA-15 ubiquitinylation was 2.5-fold
increased by serum starvation. At the opposite, it was reduced
by2-fold by TPA treatment and by overexpression of PKC-
(Fig. 9B). Both TPA and PKC- failed to decrease PED/PEA-15
ubiquitinylation in the presence of KN-93. Also, ubiquitinyla-
tion of the PEDS104G mutant was reduced in a manner compa-
rable with that of PEDWT, whereas that of the PEDS116Gmutant
did not significantly change (Fig. 9C).
Functional Relevance of Ser-116 Phosphorylation—To fur-
ther investigate the relevance of PED/PEA-15 phosphorylation
on its anti-apoptotic action, 293PEDY1 cells have been deprived
of serum for 20 h in the absence or in the presence of TPA (Fig.
10). As expected, TPA exposure largely rescued the cell death
induced by serum starvation. TPA effect was also mimicked by
PKC- overexpression in 293PEDY1 cells (Fig. 10A). However,
the incubation with KN-93 prevented both TPA and PKC-
FIGURE 6. TPA and PKC- effect on CaMKII phosphorylation. A, 293PEDY1
cells were serum-starved and treated with 1 M TPA for the indicated times.
Cell lysates were analyzed by p-CaMKII immunoblot. Filters were then rep-
robed with CaMKII Ab for normalization, and the results were quantitated by
laser densitometry. The autoradiograph shown is representative of five (for
293PEDY1) and three (for C5N) independent experiments. The error bars repre-
sent the mean  S.D. of the densitometric analysis. B, 293PEDY1 cells were
serum-starved and treated with 1 M TPA for 20 h in the absence or in the
presence of PKC-ASO or of wild-type or a dominant-negative PKC-mutant.
Cell lysates were then analyzed by immunoblot with p-CaMKII and CaMKII
Abs, and the results were quantitated by laser densitometry. The autoradio-
graph shown is representative of four independent experiments. The error
bars represent themean S.D. of the densitometric analysis. C, 293PEDY1 and
C5N cells were serum-starved and treated with 1 M TPA for 20 h. Akt/PKB
activity has beenmeasured as described previously (35). The error bars repre-
sent the mean S.D. of three independent experiments in triplicate.
FIGURE 7. Regulation of PED/PEA-15 phosphorylation and expression by
CaMKII. A, 293PEDY1 and C5N cells were serum-starved and treatedwith 1M
TPA for 20 h or transfectedwith a pcDNAIII plasmid containing a PKC- cDNA,
in the absence or in the presence of 10 M KN-93. Cell lysates were then
analyzedby immunoblotwithp-PEDS116andPEDAbs. The results havebeen
analyzed by laser densitometry, and the error bars represent themean S.D.
of the densitometric analyses obtained in four duplicate experiments.
B, HEK293 cells transfected with PEDWT, PEDS104G, and PEDS116G alone or in
combinationwith PKC- cDNA and further incubated in the absence or in the
presence of 10 M KN-93. Cell lysates were then analyzed by PKC- and PED
immunoblot, and the results were quantitated by laser densitometry. The
autoradiographs shownare representativeof four independent experiments.
The error bars represent the mean S.D. of the densitometric analyses.
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rescue of cell death, suggesting that CaMKII-induced phospho-
rylation of PED/PEA-15 at Ser-116 was required for this effect
(Fig. 10A). To further sustain this hypothesis, we have tested
TPA protection from cell death in HEK293 cells transfected
with either PEDWT or PEDS116G. Although normally inducing
survival of serum-starved cells transfected with PEDWT, TPA
effect was 2-fold reduced in cells overexpressing PEDS116G
(Fig. 10B).
DISCUSSION
Elevated expression of the anti-apoptotic protein PED/
PEA-15 has been found in transformed cell lines and confers
resistance to apoptotic stimuli (7–11, 15, 22). An increase of
PED/PEA-15 levels is also detected in the papillomatous skin of
dimethylbenzanthracene/TPA-treated mice upon experimen-
tal carcinogenesis protocols (15), further indicating that raised
PED/PEA-15 expressionmay play a role in cellular transforma-
tion. In this work, we have investi-
gated the molecular mechanisms
through which the tumor-promot-
ing agent TPA affects PED/PEA-15
expression. Two lines of evidence
indicate that, at least in part, PED/
PEA-15 expression is regulated by
TPA at the post-translational level.
Firstly, similar to previous observa-
tions in mouse skin and in keratino-
cyte cell lines (15), phorbol esters
up-regulate PED/PEA-15 protein
expression in HEK293 cells ectopi-
cally expressing the PED/PEA-15
cDNA under the transcriptional
control of the cytomegalovirus pro-
moter. In addition, in these cells, as
well as in untransfected keratino-
cytes, PED/PEA-15 regulation by
TPA also occurs in the presence of
the protein synthesis inhibitor
cycloheximide. The evidence that
TPA effect was partially reduced
by cycloheximide, however, sug-
gests that additional regulation
may occur at the transcriptional
level. Indeed, PED/PEA-15 mRNA
levels are also significantly
increased in untransfected C5N
cells following TPA stimulation.
Nonetheless, PED/PEA-15 phos-
phorylation is a major event for the
regulation of its stability (22). Here,
we show that Ser-116 is the key
phosphorylation site enabling TPA
regulation of PED/PEA-15 expres-
sion. We have previously described
that Ser-116 phosphorylation by
Akt/PKB increases PED/PEA-15
half-life following insulin stimula-
tion (22). It is unlikely that Akt/PKB
is involved in TPA control of PED/PEA-15 expression since
there is no sustainedAkt/PKB activation uponTPAexposure of
HEK293 cells and C5N keratinocytes. CaMKII is a more likely
candidate. Indeed, Kubes et al. (23) have reported that CaMKII
may also phosphorylate PED/PEA-15 at Ser-116 and, consist-
ent with findings in other cell types (31), we found that TPA
increases CaMKII activity in HEK293 and in C5N cells (Fig. 6).
In addition, the timing of CaMKII activation closely parallels
PED/PEA-15 phosphorylation at Ser-116 following TPA stim-
ulation. Finally, pharmacological inhibition of CaMKII with
KN-93 almost totally blocked TPA-induced Ser-116 phospho-
rylation. At variance, Ser-104 phosphorylation was rapidly
induced by TPA and then decreased upon prolonged incuba-
tion. Ser-104 is known to be directly phosphorylated by PKC
following endothelin-1 treatment of astrocytic cells (23). The
same occurs with TPA since the down-regulation of conven-
tional PKC isoforms after long termexposurewas accompanied
FIGURE 8. Effect of lactacystin on PED/PEA-15 expression. A, 293PEDY1 cells were treated with either PKC-
ASO or PKC-SO and further incubated in the absence or in the presence of 30 M lactacystin (Lact), as indi-
cated. Cell lysates were then analyzed by PED immunoblot, and the results were quantitated by laser densi-
tometry. The autoradiograph shown is representative of four independent experiments. The error bars
represent themean S.D. of the densitometric analysis. FCS, fetal calf serum. B, HEK293 cells transfected with
PEDWT or PEDS116G were treated with 1 M TPA or 30 M lactacystin for 20 h as indicated. C5N cells were
serum-starved and incubatedwith TPA (1mM), KN-93 (10mM), and lactacystin (30mM) as indicated. Cell lysates
were then analyzed by PED immunoblot, and the results were quantitated by laser densitometry. The autora-
diographs shown are representative of four (for HEK293) and three (for C5N) independent experiments. The
error bars represent the mean S.D. of the densitometric analyses.
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by a decline of Ser-104 phosphorylation. However, genetic
silencing of conventional and novel PKC isoforms, which are
canonical intracellular targets of TPA, further argued against
the involvement of Ser-104 phosphorylation by PKC in direct
regulation of PED/PEA-15 expression. Consistent with this, the
Ser-1043Gly mutant, but not the Ser-1163Gly mutant, was
equally sensitive to TPA action as the wild-type PED/PEA-15.
Altogether, these observations indicate that insulin and phor-
bol esters use different pathways to regulate PED/PEA-15 pro-
tein expression, both converging at the level of Ser-116 phos-
phorylation. For instance, whereas Akt/PKB is the major
candidate kinase for the insulin action (22), CaMKIImaymedi-
ate PED/PEA-15 phosphorylation at the Ser-116 in response to
TPA.The finding that LY294002 inhibition of phosphatidylino-
sitol 3-kinase activity also reduces TPA effect on PED/PEA-15
expression (data not shown)may be due to decreased activity of
other downstream molecules different from Akt/PKB.
Indeed, a pivotal role has emerged for PKC- in TPA regula-
tion of PED/PEA-15 expression. Both the antisense reduction
of PKC- and the expression of a
dominant-negative PKC- mutant
led to a decrease of TPA-regulated
PED/PEA-15 phosphorylation at
Ser-116, accompanied by a reduc-
tion of PED/PEA-15 protein levels.
This led us to hypothesize that
PKC- could either directly phos-
phorylate Ser-116 or directly affect
CaMKII activity. No PED/PEA-15
phosphorylation at Ser-116 was
induced in vitro by active recombi-
nant PKC- (data not shown). At
variance, inhibition of PKC-
expression and/or function in
HEK293 cells almost completely
abolished CaMKII induction by
TPA, supporting the hypothesis
that PKC- could affect PED/
PEA-15 expression by acting
upstream of CaMKII. Accordingly,
PKC--increased CaMKII activity
was paralleled by raised Ser-116
phosphorylation and PED/PEA-15
expression levels.Whether PKC- is
directly activated by phorbol esters
is still debated (32–34). Alterna-
tively, however, prolonged exposure
of the cell toTPA,which is known to
down-regulate conventional PKC
isoforms, may up-regulate PKC-
activity by removing the tonic inhib-
itory constraint exerted by the firsts
on the latter. This is consistent with
our previous observation, indicating
that PKC- hyperactivation causes
a downstream inhibition on PKC-
(24, 35).
Regulation of PED/PEA-15 phos-
phorylationmay be a common event, which contributes to pro-
tection from apoptosis, driven by either PKC- (36–38) or
CaMKII (39–41). Intriguingly, we have previously described
that PED/PEA-15 overexpression inhibits insulin induction of
PKC-, thereby impairing glucose uptake (24, 35). It is now
emerging that PKC- activation instead up-regulates PED/
PEA-15 protein levels, which in turn, may negatively affect
PKC- function. This is also in agreement with recent evidence
showing that forced expression of PKC- may inhibit insulin
and growth factor signaling (42–44).
Recently, Renganathan et al. (21) have proposed that PED/
PEA-15 phosphorylation at specific residues is important in
enabling its interaction with selected intracellular proteins. In
particular, phosphorylation at Ser-116 promotes its binding to
FADDand plays an important role in protecting cells from apo-
ptosis (9, 10, 21). Here, we show that Ser-116 phosphorylation
is also involved in preventing PED/PEA-15 degradation in the
26 S proteasome. Indeed, lactacystin treatment mimicked the
effect of TPA and prevented PED/PEA-15 protein loss follow-
FIGURE 9. Regulation of PED/PEA-15 ubiquitinylation. A, HEK293 cells were transfected with His-Myc-
PED/PEA-15 and HA-ubiquitin (HA-Ub) alone or in combination. Upon purification of His-Myc-PED/PEA-15
and separation on SDS-PAGE, filters were probedwith HAAb. The autoradiograph shown is representative
of five independent experiments. B, 293PEDY1 cells were serum-starved and treated with 1 M TPA for 20 h
or transfected with PKC- cDNA in the absence or in the presence of 10 M KN-93. Cell lysates were
separated on SDS-PAGE and immunoblotted with FK1 and PED Abs. The results have been analyzed by
laser densitometry, and the error bars represent the mean S.D. of the densitometric analyses obtained
in four duplicate experiments. FCS, fetal calf serum. C, HEK293 cells transfected with PEDWT, PEDS104G, and
PEDS116G were serum-starved and treatedwith 1M TPA for 20 h. Cell lysates were separated on SDS-PAGE
and immunoblotted with FK1 and PED Abs. The results have been analyzed by laser densitometry, and the
error bars represent the mean  S.D. of the densitometric analyses obtained in four duplicate
experiments.
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ing growth factor deprivation or PKC- silencing. Different
fromTPA, however, lactacystin also rescued the expression lev-
els of the non-phosphorylatable Ser-116 3 Gly mutant, indi-
cating that phosphorylation at this sitemay confer the ability to
escape proteasomal degradation. Proteasomal targeting and
degradation are typical features of ubiquitinylated proteins
(30). Sur and Ramos (45) have recently shown that vanishin, a
death effector domain protein with a high degree of homology
withPED/PEA-15, is ubiquitinylated.Wenowpresent evidence
that PED/PEA-15 directly binds ubiquitin. Treatment with
TPA as well as PKC- overexpression reduced the ubiquitiny-
lation of wild-type PED/PEA-15 but had no effect on the Ser-
116 phosphorylation-deficient mutant. Preserved ubiquitinyla-
tionwas also observed in the presence of KN-93, indicating that
CaMKII phosphorylation plays an important role in the regu-
lation of PED/PEA-15 expression by controlling its ubiquitiny-
lation state. Finally, both KN-93 and Ser-1163 Gly substitu-
tion reduced TPA anti-apoptotic action, suggesting that
CaMKII activation and PED/PEA-15 phosphorylation at Ser-
116 are relevant for this effect.
Thus, we have shown that phorbol esters up-regulate PED/
PEA-15 expression by controlling its proteasomal degradation.
PKC- and CaMKII activities are necessary to enable TPA-
dependent phosphorylation of PED/PEA-15 at Ser-116. This
phosphorylation prevents ubiquinylation and proteasomal tar-
geting and induce PED/PEA-15 intracellular accumulation,
thereby enhancing its anti-apoptotic action.
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We have examined glucose homeostasis in mice hypomorphic for the homeotic transcription factor gene
Prep1. Prep1-hypomorphic (Prep1i/i) mice exhibit an absolute reduction in circulating insulin levels but normal
glucose tolerance. In addition, these mice exhibit protection from streptozotocin-induced diabetes and en-
hanced insulin sensitivity with improved glucose uptake and insulin-dependent glucose disposal by skeletal
muscle. This muscle phenotype does not depend on reduced expression of the known Prep1 transcription
partner, Pbx1. Instead, in Prep1i/i muscle, we find normal Pbx1 but reduced levels of the recently identified
novel Prep1 interactor p160. Consistent with this reduction, we find a muscle-selective increase in mRNA and
protein levels of PGC-1, accompanied by enhanced expression of the GLUT4 transporter, responsible for
insulin-stimulated glucose uptake in muscle. Indeed, using L6 skeletal muscle cells, we induced the opposite
effects by overexpressing Prep1 or p160, but not Pbx1. In vivo skeletal muscle delivery of p160 cDNA in Prep1i/i
mice also reverses the molecular phenotype. Finally, we show that Prep1 controls the stability of the p160
protein. We conclude that Prep1 controls insulin sensitivity through the p160-GLUT4 pathway.
Prep1 is an homeodomain transcription factor belonging to
the MEINOX subfamily of the TALE (three amino acid loop
extension) proteins (32). Prep1 forms DNA-independent di-
meric complexes with all isoforms of the Pbx homeodomain
transcription factor, enhancing target specificity and regulatory
function (4, 6, 24, 36, 39).
Prep1 is an important gene in development: its downregula-
tion in zebrafish and its deletion in mice induces embryonic
lethality (9; L. C. Fernandez-Diaz and F. Blasi, unpublished
data). Hypomorphic mice expressing about 2% of Prep1
mRNA (Prep1i/i) have a leaky embryo-lethal phenotype with
major anomalies in hematopoiesis, oculogenesis, and angio-
genesis (15). About 25% of the homozygous Prep1i/i embryos
survive, and the mice are born and live a normal-length life.
However, they show defects in T-cell development (38).
In all these systems, the reduction or the absence of Prep1 is
accompanied by a reduction of its Pbx partners (9, 15, 38). The
reduction in the mouse appears to be cell type and isoform
specific (15). Direct studies have shown that the reduction of
Pbx expression is due largely to a posttranscriptional mecha-
nism (15, 38), in particular to a decrease in the protein half-life.
In fact, dimerization with Prep1 protects Pbx from proteaso-
mal degradation (26).
Previous studies also demonstrated that the generation of
Pbx-Prep heterodimers is necessary to enable nuclear localiza-
tion of Prep1 and to prevent nuclear export of Pbx (5, 20).
Indeed, the balance of Prep and Pbx has been shown to be
functionally important both during embryogenesis and in adult
life (9, 15, 26, 46).
We recently discovered that p160 Myb-binding protein
(p160) (44) is a new direct Prep1-interacting protein that com-
petes with Pbx1 for Prep1 binding (11). Thus, Prep1 functions
may depend on not only its interaction with Pbx but also that
with p160. The role of the Prep1-p160 interaction, however, is
still unknown. Interestingly, p160 is a repressor of the regulator
of glucose and energy metabolism, PPAR-gamma coactiva-
tor-1 (PGC-1) (13).
The importance of Pbx and Hox protein interaction in glu-
cose homeostasis, pancreatic cell proliferation, and pancreas
development has been studied. Transgenic mice expressing Pbx
interaction-defective Pdx1 genes were used to investigate the
requirements for Pdx1-Pbx complexes in pancreatic morpho-
genesis, islet cell differentiation, and glucose homeostasis (12).
In these studies, Pdx1-Pbx complexes were dispensable for
glucose homeostasis and differentiation of stem cells into duc-
tal, endocrine, and acinar lineages; however, they were essen-
tial for expansion of these cell populations during develop-
ment. Further studies of transheterozygous Pbx1/ Pdx1/
mice revealed in vivo genetic interactions between Pbx1 and
Pdx1 that are essential for postnatal pancreatic function (22).
Indeed, these mice developed age-dependent overt diabetes
mellitus, while Pbx1/ and Pdx1/ mice showed only re-
duced glucose tolerance. Mutations of Pdx1 protein cause di-
abetes in both mice and humans (1, 18, 27, 43), suggesting that
Pbx1 perturbation may also determine susceptibility to diabe-
* Corresponding author. Mailing address: Dipartimento di Biologia
e Patologia Cellulare e Molecolare, Universita` di Napoli Federico II,
Via Sergio Pansini, 5, Naples 80131, Italy. Phone: 39 081 746 3248. Fax:
39 081 746 3235. E-mail: beguino@unina.it.
 Published ahead of print on 21 July 2008.
5634
 at BioChiom
ica Napoli II on February 11, 2009 
m
cb.asm
.org
D
ow
nloaded from
 
tes. Whether the perturbation of other MEINOX transcription
factors, like Prep1, affects the development and function of the
endocrine pancreas and glucose tolerance is presently un-
known.
It is not known whether Prep1 has any role in glucose and
energy metabolism. Because of the ability of Prep1 to interact
with both Pbx1 and p160, we have studied glucose homeostasis
in Prep1i/i mice. We show that adult Prep1i/i animals exhibit
enhanced sensitivity to insulin action and are protected from
developing streptozotocin-induced diabetes. The increased
sensitivity to insulin in these mice is due, at least in part, to a
novel Pbx1-independent and p160-dependent mechanism. We
demonstrate, for the first time, a role for Prep1 in glucose
homeostasis mediated by the newly identified interactor p160.
MATERIALS AND METHODS
Materials. Media, sera, antibiotics for cell culture, and the Lipofectamine
reagent were from Invitrogen (Grand Island, NY). The anti-Prep1 polyclonal
antibody and pBOS-Prep1 vector were described previously (3). pSG5-Pbx1,
PSG5-Prep1HR1, and pRUFneo-p160 vectors were described previously (11).
PGC-1 and GLUT4 antibodies were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). The p160 antibody was from Zymed Laboratories (San Fran-
cisco, CA). Protein electrophoresis reagents were purchased from Bio-Rad
(Richmond, VA), and Western blotting and enhanced chemiluminescence
(ECL) reagents were from Amersham Biosciences (Arlington Heights, IL). All
other chemicals were from Sigma (St. Louis, MO).
Generation and characterization of Prep1-hypomorphic mice. Prep1 targeted
mice were generated by gene trapping by Lexikon Genetics, Inc. (The Wood-
lands, TX) and have been described (15, 38). In the experiments reported in this
paper, heterozygous mice were backcrossed with wild-type C57BL/6 mice for
four generations. All animal handling conformed to regulations of the Ethics
Committee on Animal Use of H. S. Raffaele (IACUC permission number 207).
Southern blot analysis of EcoRI-digested total DNA from tail biopsy specimens
or yolk sacs was accomplished through a 132-bp double-stranded Prep1 cDNA
probe prepared from full-length Prep-1 cDNA with the forward primer 5-ATG
ATGGCGACACAGACGCTAAGTATA-3 and the reverse primer 5-GGGG
TCTGAGACTCGATGGGAGGAGGACTC-3. The PCR genotyping strategy
employed the oligonucleotides Prep-R1 and LTR2 (sequences provided below),
which amplify a 230-bp fragment in the disrupted allele, while the Prep-F1–
Prep-R1 pair amplifies a 300-bp fragment of the wild-type allele. Sequences of
oligonucleotides are as follows: Prep-F1, 5-CCAAGGGCAGTAAGAGAAGC
TCTGGAG-3; Prep-R1 5GGAGTGCCAACCATGTTAAGAAGAAGTCC
C-3; LTR2, 5CAAAATGGCGTTACTTAAGCTAGCTTGCC-3.
Pancreatic islet sections were stained with hematoxylin and eosin. For mor-
phometry, pancreases were obtained from 3-month-old control and hypomorphic
littermate mice, and immunohistochemical detection of insulin and glucagon was
performed in three sections (2 to 3 m) separated by 200 m, as described in
reference 10.
Tissue samples (tibialis muscles and pancreases) were collected rapidly after
mice were sacrificed by pentobarbitone overdose. Tissues were snap-frozen in
liquid nitrogen and stored at 80°C for subsequent Western blotting.
Mouse phenotyping. Blood glucose levels were measured with a glucometer
(A. Menarini Diagnostics); insulin and glucagon were measured by radioimmu-
nological assay (RIA) with a rat insulin standard (insulin rat RIA kit; Linco
Research, St. Charles, MO) and glucagon standard (glucagon RIA kit; Linco
Research).
For glucose and insulin tolerance tests, mice fasted overnight and then were
injected with glucose (2 g  kg of body weight1) intraperitoneally. Venous blood
was drawn by tail clipping at 0, 15, 30, 45, 60, 90, and 120 min without reclipping
of the tails. For insulin tolerance, random-fed mice were injected intraperitone-
ally with insulin (0.75 mU  g of body weight1) (Eli Lilly, Indianapolis, IN).
Venous blood was subsequently drawn by tail clipping at 0, 15, 30, 45, 60, 90, and
120 min after insulin injection to determine blood glucose levels. To assess ex
vivo insulin secretion, islets were isolated from 6-month-old mice by collagenase
digestion and subsequent centrifugation on a Histopaque (Sigma-Aldrich) gra-
dient (23) A total of 20 islets were manually selected and preincubated in
Dulbecco’s modified Eagle’s medium (Life Technologies) at 37°C in a 5% CO2
atmosphere for 24 h. Islets were further incubated in Krebs-Ringer buffer (120
mmol/liter NaCl, 1.2 mmol/liter MgSO4, 5 mmol/liter KCl, 10 mmol/liter
NaHCO3, 1.3 mmol/liter CaCl2, and 1.2 mmol/liter KH2PO4) for 30 min and then
stimulated at 37°C with various concentrations of glucose for 1 h. Islets were
subsequently collected by centrifugation, and supernatants were assayed for
insulin content by RIA.
For low-dose streptozotocin treatment, mice fasted for 6 h prior to intraper-
itoneal (i.p.) injection with streptozotocin (40 mg/kg body weight) dissolved in
sterile citrate buffer or with the vehicle, citrate buffer (0.05 M sodium citrate, pH
4.5). Streptozotocin was administered for five consecutive days, and glycemia and
body weight were measured during the next 4 weeks. Some mice were sacrificed
during the streptozotocin treatment to evaluate the morphological alteration of
the pancreas.
In vivo glucose utilization. An intravenous flash injection of 1 Ci of the
nonmetabolizable glucose analog 2-[1-3H]deoxy-D-glucose (2-DG) (Amersham
Pharmacia Biotech) and an i.p. injection of insulin (0,75 mU  g of body
weight1) were administered to random-fed mice. The specific blood 2-DG
clearance was determined with 25-l blood samples (tail vein) obtained 1, 10, 20,
and 30 min after injection using the Somogyi procedure (42). Tibialis skeletal
muscle tissue samples were removed 30 min after injection. The glucose utiliza-
tion index was determined by measuring the accumulation of radiolabeled com-
pounds (14). The amount of 2-DG–6 phosphate per milligram of protein was
divided by the integral of the concentration ratio of 2-DG to unlabeled glucose
measured. Glucose utilization is expressed as picomoles per milligram of protein
per minute.
p160 gene delivery in skeletal muscle of Prep1-hypomorphic mice. We adopted
an established technique (19, 40) to inject mouse tibialis muscles with 100 g of
pRUFneo-p160 naked DNA (encoding a Flag-tagged p160 cDNA), using 1-ml
syringes and 27-gauge needles. After 48 h, mice were sacrificed and muscles were
processed for RNA and/or protein extraction as described in the appropriate
section.
FIG. 1. Insulin and glucagon levels in Prep1-hypomorphic mice.
For determination of circulating insulin (A) and glucagon (B) levels,
control and hypomorphic mice fasted overnight and were then injected
with glucose (3 g/kg body wt) intraperitoneally. Plasma insulin concen-
trations were quantitated at the indicated times by radioimmunoassay.
Glucagon levels were assessed in the fasting state. Data are means plus
standard deviations for 12 mice/group. Asterisks indicate statistically
significant differences (*, P  0.05; **, P  0.01).
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Cell culture procedures and transfection. L6 skeletal muscle cells were cul-
tured at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum, 2% L-glutamine, 10,000 U/ml penicillin, and 10,000
g/ml streptomycin. Transient transfection of Prep1, Prep1HR, p160, and Pbx1
plasmids or small interfering RNA oligonucleotides was performed by the
Lipofectamine method according to the manufacturer’s instructions. For these
studies, 60 to 80% confluent cells were washed twice with Optimem (Invitrogen)
and incubated for 8 h with 5 g of plasmid construct or with 12 g of oligonu-
cleotides and 45 to 60 l of Lipofectamine reagent. The medium was then
replaced with DMEM with 10% fetal calf serum, and cells were further incu-
bated for 15 h before being assayed.
2-DG uptake by the L6 cells was measured as previously reported (7). Briefly,
confluent cells were incubated in DMEM supplemented with 0.25% albumin for
18 h at 37°C. The medium was aspirated, and cells were further incubated for 30 min
in glucose-free HEPES buffer (5 mmol/liter KCl, 120 mmol/liter NaCl, 1.2 mmol/
liter MgSO4, 10 mmol/liter NaHCO3, 1.2 mmol/liter KHPO4, and 20 mmol/liter
HEPES [pH 7.8]; 2% albumin). The cells were incubated with 100 nmol/liter insulin
for 30 min, supplemented during the final 10 min with 0.2 mmol/liter [14C]2-DG.
Cells were then solubilized, and 2-DG uptake was quantitated by liquid scintillation
counting.
Western blot analysis and immunoprecipitation procedures. Tissue samples
were homogenized in a Polytron (Brinkman Instruments) in 20 ml T-PER re-
agent per gram of tissue according to manufacture (Pierce). After centrifugation
at 10,000 rpm for 5 min, supernatant was collected. Cells were solubilized in lysis
buffer (50 mmol/liter HEPES [pH 7.5], 150 mmol/liter NaCl, 10 mmol/liter
EDTA, 10 mmol/liter Na4P2O7, 2 mmol/liter Na3VO4, 100 mmol/liter NaF, 10%
glycerol, 1% Triton X-100, 1 mmol/liter phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin) for 1 h at 4°C, and lysates were centrifuged at 5,000  g for 20 min.
Total or immunoprecipitated homogenates were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
0.45-m Immobilon-P membranes. Upon incubation with primary and secondary
antibodies, immunoreactive bands were detected by ECL according to the man-
ufacturer’s instructions (30).
Real-time reverse transcription (RT)-PCR analysis. Total cellular RNA was
isolated from tibialis muscle and L6 cells by using an RNeasy kit (Qiagen Sciences),
according to manufacturer’s instructions. One microgram of tissue or cell RNA was
reverse transcribed using Superscript II reverse transcriptase (Invitrogen). PCR
products were analyzed using Sybr green mix (Invitrogen). Reactions were per-
formed using Platinum Sybr green qPCR Super-UDG using an iCycler IQ multi-
color real-time PCR detection system (Bio-Rad). All reactions were performed in
triplicate, and -actin was used as an internal standard. Primer sequences used were
as follows: GLUT4 R, 5-AATGATGCCAATGAGAAAGG-3; GLUT4 F, 5-CA
GAAGGTGATTGAACAGAG-3; Prep1-R, 5-GGAGTGCCAACCATGTTAA
GAAGAAGTCCC-3; Prep1-F, 5-GACACCGTGTGCTTCTCGCTCAAG-3;
P160 R, 5-AGACAAGCAATGTACCGACTACAG-3; P160 F, 5-GGCTCTGG
TGGACATCCTCTC-3; PGC-1 R, 5-AGGGTCATCGTTTGTGGTCAG-3;
PGC-1 F, 5CAGCGGTCTTAGCACTCAG-3; Pbx1 R, 5-TCATGATCCTGC
GCTCCCGGTTCCTGGAT-3; Pbx1 S, 5-GATGCCCTGCGGACTGTACATCT
GACTG-3; -actin F, 5-GCGTGACATCAAAGAGAAG-3; and -actin R, 5-
ACTGTGTTGGCATAGAGG-3.
Statistical procedures. Data were analyzed with Statview software (Abacus
Concepts) by one-factor analysis of variance. P values of less than 0.05 were
considered statistically significant. The total area under the curve for glucose
response during the insulin tolerance test was calculated by the trapezoidal
method (45).
RESULTS
Prep1-hypomorphic mice are protected from streptozotocin-
induced hyperglycemia. To address the role of Prep1 in glucose
metabolism, we compared wild-type, Prep1i/, and Prep1i/i lit-
FIG. 2. Glucose tolerance tests in Prep1-hypomorphic mice. Six groups (22/group) of male and female Prep1-hypomorphic and control mice
were analyzed at 3 and 12 months of age. Following determinations of basal glycemias, mice were injected intraperitoneally with glucose (2
mg  kg1), followed by further blood glucose level determinations at the indicated times as described in Materials and Methods. Data are means	
standard deviations for each group of animals. Areas under the curves showed no significant difference between groups.
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termate mice. We observed a gene dosage-dependent reduc-
tion in plasma insulin levels both under fasting conditions and
upon glucose loading (Fig. 1A). As with insulin, circulating
glucagon levels were also depressed in the Prep1-hypomorphic
mice (Fig. 1B).
In spite of the absolute reduction in the insulin levels, i.p.
glucose loading indicated preserved glucose tolerance in both
the Prep1i/and Prep1i/i mice, with no gender-related difference
(Fig. 2). In addition, glucose tolerance remained normal in
12-month-old hypomorphic mice, suggesting protection of
these animals from developing glucose tolerance abnormali-
ties. To analyze this hypothesis further, we targeted -cell
function in the Prep1-hypomorphic mice with low-dosage (40
mg/kg) streptozotocin administration. As shown in Fig. 3A,
this treatment reduced fasting plasma insulin levels by almost
40% in both Prep1i/ and wild-type littermates. By day 12 of
streptozotocin treatment, the wild-type mice developed overt
hyperglycemia, accompanied by a 12% reduction in body
weight (P 0.05; Fig. 3B and C). In contrast, the Prep1i/ mice
showed twofold-smaller changes in plasma glucose levels with
no significant weight loss. These data show that, despite their
absolute hypoinsulinemia, Prep1i/ mice are protected from
streptozotocin-induced diabetes. Similar experiments could
not be performed on homozygous Prep1i/i mice because of their
frailness.
Prep1 gene hypomorphism causes enhanced insulin sensi-
tivity in glucose disposal. TUNEL (terminal deoxynucleotidyl-
FIG. 3. Effect of streptozotocin in Prep1-hypomorphic mice. Het-
erozygous hypomorphic and control mice (12 mice/group) were sub-
jected to daily i.p. administrations of either streptozotocin (40 mg/kg)
or citrate buffer for five consecutive days as described in Materials and
Methods. Fasting plasma insulin levels (A) and body weight (C) were
assessed both before and 12 days after the end of the treatment. Blood
glucose levels (B) were measured before and at the indicated times
after streptozotocin administration. Data are means 	 standard devi-
ations of values obtained from each group of animals. Asterisks denote
statistically significant differences (*, P  0.05; **, P  0.01).
FIG. 4. Insulin action on glucose disposal in Prep1-hypomorphic
mice. (A) Six-month-old Prep1-hypomorphic and control mice (23/
group) were i.p. injected with insulin (0.75 mU/g body weight) followed
by determinations of blood glucose levels at the indicated times. Data
are means 	 SD for each group of mice. (B) Prep1i/ and control mice
were subjected to intravenous flash injection of 1 Ci of 2-DG and to
i.p. injection of insulin (0.75 mU/g of body weight). Tibialis muscles
were removed after 30 min and snap-frozen in liquid nitrogen. 2-DG
accumulated in muscle tissue was quantitated as described in Materials
and Methods (B). Data are means plus standard deviations for 10
mice/group. Asterisks denote statistically significant differences (*, P
0.05; ***, P  0.001).
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transferase-mediated dUTP-biotin nick end labeling) assays
revealed no difference in streptozotocin-induced -cell apop-
tosis in hypomorphic and control mice (data not shown). We
hypothesized therefore that the protection from development
of hyperglycemia observed in the Prep1-hypomorphic mice
could result from improved insulin sensitivity of glucose dis-
posal. Indeed, upon i.p. insulin injection, the Prep1i/ heterozy-
gous and Prep1i/i homozygous mice developed more sustained
and prolonged hypoglycemia than control mice (glucose area-
under-the-curve difference between hypomorphic and control
mice was significant at the P  0.001 level), with a Prep1 gene
dosage effect (Fig. 4A). Importantly, in vivo insulin-mediated
2-DG uptake by the skeletal muscle was almost 2.5- and 3.5-
fold improved, respectively, in the Prep1i/ and in the Prep1i/i
mice (Fig. 4B). These results suggested a molecular mecha-
nism operating in skeletal muscle and compensating for the
absolute hypoinsulinemia caused by Prep1 deficiency.
Skeletal muscle from Prep1-hypomorphic mice shows al-
tered expression of GLUT4, PGC-1, and p160. To address the
mechanisms responsible for increased insulin-mediated glu-
cose disposal in Prep1-hypomorphic mice, we investigated the
expression of several proteins playing an important role in
insulin sensitivity and glucose disposal. Protein levels mea-
sured by immunoblotting of insulin receptor (IR), IR substrate
1 (IRS-1), IRS-2, Akt/PKB, PKC-
, ERK1/2, and Pbx1 were
not significantly different in Prep1i/i, Prep1i/, and control mice
(Fig. 5A). Interestingly, however, GLUT4 expression was in-
creased by 75 and 25%, respectively, in skeletal muscle of
Prep1i/i and Prep1i/ mice, at both the protein and the mRNA
levels (Fig. 5A and B). Similar to GLUT4, the mRNA and
protein expression of PGC-1 (29) was also upregulated in the
muscle of Prep1-hypomorphic mice. The protein (though not
the mRNA) levels of the PGC-1 repressor and Prep1-binding
Pbx competitor p160 were reduced by 30 and 50%, respec-
tively, in the Prep1i/ and the Prep1i/i mice (Fig. 5A and B). At
variance from muscle, liver expression of p160 as well as of
PGC-1 exhibited no difference in Prep1-hypomorphic and in
control mice, indicating tissue selectivity in Prep1 action (data
not shown).
P160 has been shown to directly interact with Prep1 in var-
ious cell lines (11). We also obtained evidence of Prep1-p160
interaction in tibialis muscle extracts of wild-type mice by im-
munoprecipitating with anti-Prep1 and blotting with p160 an-
tibodies (Fig. 5C). Indeed, reduced coimmunoprecipitation
was noted in the Prep1i/ extracts, with no interaction in the
Prep1i/i extracts. These findings raised the possibility that, in
the skeletal muscle, Prep1 downregulation results in activation
of the glucose transport machinery by decreasing p160 levels.
p160 mediates Prep1-dependent GLUT4 downregulation in
L6 skeletal muscle cells. We analyzed this hypothesis further
by transiently transfecting Prep1 cDNA in differentiating L6
skeletal muscle cells, leading to a ninefold overexpression of
Prep1 in these cells (Fig. 6A). Consistent with the findings in
muscles of hypomorphic mice, overexpression of the wild-type
Prep1 cDNA determined a 70% inhibition of insulin-stimu-
lated 2-DG uptake by these cells (Fig. 6B) and a similar decline
in the expression of GLUT4 protein and mRNA (Fig. 6A and
C). These effects were accompanied by a threefold decline in
PGC-1 protein and mRNA levels (Fig. 6A and D) and op-
posite changes in the levels of p160 protein (though p160
mRNA remained unchanged) (Fig. 6A and E).
To test for the specificity of the Prep1 effect, we transfected
the Prep1HR1 mutant, in which two leucines of the HR1 region
of Prep1 are mutated to alanine, which prevents binding to
both Pbx1 and p160 (11). Transfection with the Prep1HR1
mutant had no effect either on GLUT4, PGC-1, p160, and
Pbx1 protein levels (Fig. 6A) or on 2-DG uptake (Fig. 6B).
However, transfection of p160 cDNA blocked GLUT4 and
PGC-1 expression to an extent comparable to that caused by
Prep1 (Fig. 6A) and decreased 2-DG uptake (Fig. 6B). Pbx1
levels were low in the L6 cells and did not change upon trans-
fection with Prep1 cDNA but were further decreased by p160
(Fig. 6A). Overexpression of Pbx1, on the other hand, caused
a twofold increase in PGC-1 and GLUT4 levels (Fig. 6A), a
similar decrease of p160 (Fig. 6A), and an increase in 2-DG
uptake (Fig. 6B).
Delivery of p160 in skeletal muscle reverts the Prep1i/i phe-
notype. Next, we injected 100 g of p160 cDNA into the tibialis
muscles of wild-type, heterozygous, and homozygous litter-
mate mice. Consistent with the above findings, ectopic expres-
sion of p160 in tibialis muscles of Prep1i/i and Prep1i/ mice by
naked DNA delivery markedly reduced PGC-1 and GLUT4
levels, thereby rescuing the molecular phenotype (Fig. 7). The
introduction of p160 cDNA into the muscles of wild-type mice
also led to a reduction of PGC-1 and GLUT4. The data are
therefore consistent with the view that Prep1 downregulates
PGC-1 and GLUT4, and thereby the insulin-dependent glu-
cose transport machinery, through p160 and not Pbx1.
Prep1 regulates proteasomal degradation of p160. Prep1
controls the half-life of Pbx at the protein stability level (15,
26). To test whether Prep1 can likewise regulate the stability of
p160, we exposed L6 myotubes to the protein synthesis inhib-
itor cycloheximide and found that this treatment reduced p160
cellular levels in a time-dependent manner (Fig. 8A). Interest-
ingly, the degradation of p160 in the presence of cycloheximide
was abolished in the Prep1-overexpressing cells, implying that,
FIG. 5. Expression profile of skeletal muscle from Prep1-hypomorphic mice. (A) Tibialis muscles from Prep1-hypomorphic and control mice
were dissected, solubilized, and subjected to Western blotting with IR, IRS1, IRS2, Akt, PKC
, ERK-1/2, GLUT4, PGC-1, p160, and Pbx1
antibodies. Blots were revealed by ECL and autoradiography, and bands were quantitated by laser densitometry and normalized for actin. Data
are means plus standard deviations of duplicate determinations for 12 mice/group. (B) The abundance of RNAs for the indicated proteins was
determined by real-time RT-PCR analysis of total RNA isolated from tibialis muscles of the hypomorphic and control mice, using beta-actin as
an internal standard. Data are means plus standard deviations for four independent experiments in each of which reactions were performed in
triplicate using the pooled total RNAs obtained from six mice/genotype. (C) Protein lysates (250 g) from tibialis muscles of wild-type and
Prep1-hypomorphic mice were precipitated with Prep1 antibody or with nonimmune mouse immunoglobulin G (mIgG) followed by blotting with
p160 antibody, ECL, and autoradiography. The same lysates were directly blotted with antiactin antibodies for normalization. The autoradiograph
shown is representative of four independent experiments.
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FIG. 6. Effect of Prep1 overexpression in L6 skeletal muscle cells. (A) L6 myotubes were transiently transfected with the Prep1, Prep1HR1
mutant, p160, and Pbx1 cDNAs or with the empty vector (CTRL). Cells were solubilized, and lysates were analyzed by SDS-PAGE and subjected
to Western blotting with GLUT4, PGC-1, p160, and Pbx1 antibodies. As a control, filters were reblotted with actin antibodies. Bands were revealed
by ECL and autoradiography. The autoradiograph shown is representative of five independent experiments. (B) L6 myotubes transfected with the
Prep1, Prep1HR1 mutant, p160, and Pbx1 cDNAs or with the empty vector (CTRL) were exposed to 100 nM insulin, and 2-DG uptake was assayed
as described in Materials and Methods. Data are means plus standard deviations from four independent experiments, each in duplicate. (C, D, and
E) Levels of mRNAs encoding GLUT4, PGC-1, and p160 in cells transfected with the Prep1, Prep1HR1 mutant, p160, and Pbx1 cDNAs were
quantitated by real-time RT-PCR analysis, using beta-actin as an internal standard. Data are means plus standard deviations from four
independent experiments.
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at least in part, upregulation of p160 by Prep1 (Fig. 6) involves
posttranslational mechanisms. To better define these events,
we also incubated L6 cells with the proteasome inhibitor
MG132. As shown in Fig. 8B, exposure to this agent for 6 h
increased p160 intracellular levels by 10-fold. In the Prep1
overexpressing cells, the proteasome inhibitor induced a fur-
ther 2.5-fold accumulation of the protein. Also, in these same
cells, p160-Prep1 coprecipitation was 3-fold more effective
than in cells expressing only their physiological complement of
Prep1 (Fig. 8C). These data indicate that Prep1 interaction
enhances p160 protein stability and explain the mechanism of
p160 decrease in Prep1i/i muscle. Thus, we conclude that the
Prep1 function on glucose disposal depends on its interaction
with p160. This represents the first identified Pbx1-indepen-
dent function of Prep1.
Effect of Prep1 deficiency on islet development and islet
function. As the Prep1 partner Pbx1 is required for pancreas
development and adult function (22), and in view of the lower
insulin and glucagon plasma level of Prep1i/i mice, we also
tested whether Prep1 deficiency has an effect on endocrine
pancreas function. We first compared islet morphology in adult
(3-month-old) Prep1i/, Prep1i/i, and wild-type littermates. In
these animals, pancreas weight correlated with the genotype,
being lowest in the homozygous Prep1i/i mice (Table 1). How-
ever, the percentage of the area occupied by islets, including
both  and  cells, was normal. Also, whole-islet and -cell
masses were decreased in the Prep1i/i mice. The heterozy-
gous Prep1i/ mice displayed an intermediate phenotype
(Table 1). This phenotype could be assessed by histological
and immunohistochemical examination of pancreatic sec-
tions (Fig. 9) showing smaller islets, with normal spatial
distribution of  and  cells. The smaller size of the islets is
consistent with the reduced plasma levels of insulin and
glucagon (see Fig. 1).
Since Prep1 stabilizes Pbx1 (15) and since Pbx1 is important in
pancreas development and glucose tolerance (22), we measured
FIG. 7. p160, PGC-1, and GLUT4 levels in Prep1-hypomorphic mice injected with pRUFneo-p160 vector. Mouse tibialis muscles were
injected with 100 g of pRUFneo-p160 vector. RNA was extracted 48 h later to measure p160 (A), PGC-1 (B), and GLUT4 (C) levels. The
abundance of the indicated mRNA was determined by real-time RT-PCR analysis of total RNA isolated from tibialis muscles of the wild-type,
Prep1i/, and Prep1i/i and control mice, using beta-actin as an internal standard. Data are means plus standard deviations for three independent
experiments in each of which reactions were performed in triplicate using pooled total RNAs from three mice/genotype. (D) Proteins were also
extracted as described in Materials and Methods and analyzed by immunoblotting with specific antibodies.
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Pbx-1 levels in pancreatic tissue by immunoblotting. As shown in
Fig. 10A, Pbx1 levels were severely reduced in extracts of Prep1-
hypomorphic pancreas. Again, the extent of this reduction corre-
lated with the genotype. Other Pbx isoforms as well as p160 show
a reduction similar to that of Pbx1 (data not shown). Importantly,
however, islets isolated from the Prep1-hypomorphic and control
littermates mice exhibited comparable insulin secretion responses
when exposed to 16.7 mM glucose-containing culture medium
FIG. 8. Effect of cycloheximide and MG132 on p160 levels. L6 skeletal muscle cells overexpressing Prep1 or transfected with the empty vector
(CTRL) were incubated with 40 g/ml cycloheximide (CHX) for the indicated times (A) or 10 M MG132 for 3 h (B). Cell lysates were separated
by SDS-PAGE and analyzed by Western blotting with p160 and actin antibodies. Blots were revealed by ECL and autoradiography. The
autoradiographs shown are representative of four (A) and five (B) independent experiments. (C) L6 cells were transiently transfected with either
a cDNA encoding Prep1 or a control vector. Aliquots of the cell lysates were precipitated with Prep1 or with nonimmune mouse IgG (mIgG)
antibodies followed by blotting with p160 antibodies. Blots were revealed by ECL and autoradiography. The same lysates were directly blotted with
antiactin antibodies for normalization. The autoradiographs shown are representative of four independent experiments.
TABLE 1. Morphometric analysis of Prep1 hypomorphic pancreasa
Mouse group Islet area/pancreatic area
% in islet Wt or mass (mg)
Beta cells Alpha cells Other cells Pancreas Islet cells Beta cells
Control 0.54 	 0.07 77.21 	 4.52 17.15 	 2.10 5.64 	 1.06 179 	 15 0.97 	 0.10 0.75 	 0.06
Prep1i/ 0.50 	 0.04 76.54 	 3.11 15.75 	 2.25 7.71 	 1.44 144 	 11* 0.72 	 0.08* 0.57 	 0.03*
Prep1i/i 0.48 	 0.04* 77.32 	 2.12 16.33 	 3.24 6.35 	 0.82 127 	 9* 0.61 	 0.04** 0.47 	 0.02**
a Mice were analyzed as described in Materials and Methods. Data are means 	 standard deviations for eight Prep1i/ and an equal number of Prep1i/i and wild-type
(control) mice. Asterisks indicate statistically significant differences (*, P  0.05; **, P  0.01).
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(Fig. 10B), suggesting that Prep1 deficiency has no effect on the
insulin secretion machinery.
DISCUSSION
We have shown that Prep1-hypomorphic mice have a com-
plex phenotype with at least two metabolically relevant fea-
tures. One is increased insulin sensitivity in skeletal muscle
accompanied by protection from streptozotocin-induced dia-
betes. The second is pancreatic islet hypoplasia accompanied
by absolute hypoinsulinemia.
So far, the Pbx proteins have been considered the unique
partners of Prep1 (8, 4, 21, 33, 34, 35). However, it was recently
shown that p160 can compete with Pbx1 for binding to Prep1
(11), although the functional in vivo relevance of this interac-
tion is unknown. Pbx1 has a major role in pancreas develop-
ment, as Pbx1/ embryos feature pancreatic hypoplasia as
well as defective endocrine and exocrine cell differentiation
prior to death at embryonic day 15 to 16 (22, 41). An important
role of Pbx1 in pancreatic adult function is also shown by the
reduced glucose tolerance phenotype of heterozygous Pbx1/
mice and by the overt diabetic phenotype of the compound
Pbx1/ Pdx1/ mice (22). In the present paper, however, we
show that the increased insulin sensitivity occurring in the
skeletal muscle of Prep1i/ and Prep1i/i mice does not depend
on Pbx1. First, Pbx1 mRNA and protein levels were unchanged
in skeletal muscle (unlike other organs) (Fig. 5A and B and
Fig. 10). Second, studies with L6 cells show that overexpression
of Prep1 and Pbx1 have opposite effects. Prep1 reduces the
level of PGC-1 and GLUT4 in these cells (Fig. 6). Overex-
pression of Pbx1, on the other hand, boosts the levels of
PGC-1 and GLUT4. Thus, Pbx1 and Prep1 have opposite
effects on insulin-dependent glucose disposal by muscle.
At variance with Pbx1, p160 is key to Prep1 action on glu-
cose disposal, consistent with the known function of p160 in
regulating PGC-1 and energy metabolism in skeletal muscles
FIG. 9. Immunohistochemical analysis of islets from Prep1-hypo-
morphic mice. Formalin-fixed and paraffin-embedded pancreas sec-
tions from 3-month-old Prep1i/, Prep1i/i, and wild-type (WT) mice
were stained with hematoxylin-eosin (H & E) or immunostained with
insulin or glucagon antibodies. Microphotographs are representative
of findings obtained from 12 heterozygous, 7 homozygous, and 8 wild-
type mice. Magnification, 100.
FIG. 10. Pbx1 expression and islet function in Prep1-hypomorphic
mice. (A) Upon sacrifice, pancreases from hypomorphic and control
mice were rapidly removed as described in Materials and Methods,
solubilized, and subjected to Western blotting with Pbx1 antibodies.
Specific bands were revealed by ECL and autoradiography, followed
by densitometric quantitation. Data are means plus standard devia-
tions for 15 mice/group. (B) Islets from 6-month-old control and Prep1-
hypomorphic mice were dissected and cultured as described in Mate-
rials and Methods. Islets were exposed to the indicated concentrations
of glucose, and insulin release was assessed in the culture media by
radioimmunoassay. Data are means plus standard deviations from 10
independent experiments done in duplicate.
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(13). Indeed, we show that Prep1 increases the levels of p160
in muscle cells (Fig. 6). Overexpression of p160 in the L6
cells and direct delivery of a p160 cDNA in the muscle of
Prep1i/ and Prep1i/i mice mimic the effect of Prep1, decreasing
PGC-1 and GLUT4 expression. No change of PGC-1
mRNA or protein was detected in the liver of the Prep1-
hypomorphic mice (data not shown), suggesting that the inter-
plays between these molecules are cell type selective. To-
gether, these data are in agreement with several published
papers reporting a positive correlation between PGC-1 and
GLUT4 in rodent (29) and human (2) muscle cells and in
humans in vivo (37) and may account for the enhanced insulin
sensitivity in muscles of Prep1-hypomorphic mice (Fig. 6). Pre-
vious work by Miura et al. demonstrated GLUT4 downregu-
lation in transgenic mice overexpressing PGC-1 (31). How-
ever, as suggested by those authors, a reduction in the lower-
molecular-weight PGC-1 form might have caused the
negative correlation between PGC-1 and GLUT4 levels in
this model.
Cycloheximide experiments demonstrated that the regula-
tion of the p160 expression by Prep1 was, at least in part,
posttranslational. Furthermore, the stabilizing effect of MG132
shows that p160 degradation involves the proteasome. In the
presence of excess Prep1, the proteasome inhibitor had a much
smaller effect (Fig. 8), indicating that Prep1 interaction stabi-
lizes p160 and induces p160 escape from proteasomal degra-
dation.
The present results highlight a novel regulatory mechanism
of insulin sensitivity occurring in the skeletal muscle upstream
of the p160/PGC-1 complex and operated by the balance of
p160 and Pbx1. When p160 exceeds Pbx1, it binds Prep1, is
stabilized, and represses GLUT4 and insulin sensitivity. When
Pbx1 is present in excess, the reverse occurs. These regulatory
mechanisms must be more complex, however, since one would
otherwise expect that a decrease in Pbx1 would directly lead to
decreased insulin sensitivity, which is not the case. Indeed,
Pbx1/ mice display a slightly improved insulin sensitivity
accompanied by early impairment of glucose tolerance (22).
These mice differ from both the Prep1i/i and the Prep1i/ mice,
which show a significant enhancement in insulin sensitivity and
exhibit no tendency to develop abnormal glucose tolerance.
Furthermore, Prep1-hypomorphic mice are protected from
streptozotocin-induced diabetes in spite of their decreased
-cell mass and circulating insulin levels. Based on TUNEL
assays, this protection was independent of differences in strep-
tozotocin-induced -cell apoptosis between the hypomorphic
and control mice (data not shown). The increase in the sensi-
tivity to insulin action on glucose disposal and on glucose
uptake by the skeletal muscle, together with the reduced glu-
cagon levels, may contribute to the stability of glucose toler-
ance in the Prep1-hypomorphic mice.
Another important aspect of our work is that Prep1 and
Pbx1 have distinct roles in pancreas function in the adult.
Indeed, Prep1 binds and stabilizes Pbx proteins in a cell-spe-
cific manner (15, 26, 38, 46). Consistently, we show that the
level of Pbx1 in Prep1i/i hypomorphic mice is decreased in the
adult pancreas (Fig. 10A), though not in the skeletal muscle
(Fig. 6). Therefore, the Prep1i/i animals were expected to dis-
play a pancreatic phenotype similar to that of Pbx1/ mice,
i.e., disrupted architecture of the pancreatic islets and hypoin-
sulinemia (22). Surprisingly, Prep1-hypomorphic mice were
found to have normal islet architecture. However, they did
show islet hypoplasia, accompanied by significantly reduced
absolute insulin levels (both basal and postloading). Why the
pancreatic phenotype of the Prep1i/i mice, which includes a
strong reduction of Pbx1 pancreas expression (Fig. 10A), is
different from that of the Pbx1/ heterozygous mice (22) is
not completely clear. The deficiency of Prep1 might have been
complemented by the overexpression of other family members.
This is unlikely, however, as no increase of Prep2 or Meis
proteins is observed in Prep1i/i embryos (15). More simply, the
reduction of Pbx1 in Prep1-hypomorphic mice may not be
enough to generate the phenotype of the Pbx/ mouse. It is
also possible that other TALE family members (e.g., one of the
Meis genes) cooperate with Pbx1 in pancreas development and
in functions where Prep1 is not involved. Finally, it is possible
that the islet phenotype of the Prep1-hypomorphic mice is
established as an adaptive response to their enhanced insulin
sensitivity. Indeed, islets isolated from Prep1i/ mice exhibit a
normal secretory response to glucose in culture (Fig. 10B). A
decreased -cell mass in conditions of chronically improved
insulin sensitivity has been previously observed in mice. For
instance, pancreatic -cell area is decreased in protein tyrosine
phosphatase 1b-deficient mice owing to increased peripheral
insulin sensitivity and reduced insulin requirement (25).
The present results may have clinical relevance. In individ-
uals with normal glucose tolerance, insulin sensitivity and se-
cretion span a wide range and are determined by a number of
different genes (16, 28). Variability in some of these genes is
known to provide an important contribution to major human
disorders, including type 2 diabetes (16, 17). For example,
Pdx1 point mutations cause impaired insulin secretion and a
rare form of non-insulin-dependent diabetes formerly termed
MODY4 (43). On the basis of the results of this study, Prep1
might also be involved in the pathogenesis of these diseases.
Whether genetic variability at the Prep1 locus affects insulin
sensitivity in humans is an important issue presently under
investigation in the laboratory.
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Abstract
Aims/hypothesis Overproduction of phosphoprotein
enriched in diabetes (PED, also known as phosphoprotein
enriched in astrocytes-15 [PEA-15]) is a common feature of
type 2 diabetes and impairs insulin action in cultured cells
and in mice. Nevertheless, the potential role of PED in
diabetic complications is still unknown.
Methods We studied the effect of PED overproduction and
depletion on kidney function in animal and cellular models.
Results Transgenic mice overexpressing PED (PEDTg)
featured age-dependent increases of plasma creatinine
levels and urinary volume, accompanied by expansion of
the mesangial area, compared with wild-type littermates.
Serum and kidney levels of TGF-β1 were also higher in 6-
and 9-month-old PEDTg. Overexpression of PED in human
kidney 2 cells significantly increased TGF-β1 levels,
SMAD family members (SMAD)2/3 phosphorylation and
fibronectin production. Opposite results were obtained
following genetic silencing of PED in human kidney 2
cells by antisense oligonucleotides. Inhibition of phospho-
lipase D and protein kinase C-β by 2-butanol and
LY373196 respectively reduced TGF-β1, SMAD2/3 phos-
phorylation and fibronectin production. Moreover, inhibi-
tion of TGF-β1 receptor activity and SMAD2/3 production
by SB431542 and antisense oligonucleotides respectively
reduced fibronectin secretion by about 50%. TGF-β1
circulating levels were significantly reduced in Ped knock-
out mice and positively correlated with PED content in
peripheral blood leucocytes of type 2 diabetic patients.
Conclusions/interpretation These data indicate that PED reg-
ulates fibronectin production via phospholipaseD/protein kinase
C-β and TGF-β1/SMADpathways in kidney cells. Raised PED
levels may therefore contribute to the abnormal accumulation of
extracellular matrix and renal dysfunction in diabetes.
Keywords Diabetic nephropathy . PEA-15 . PED . PKC .
TGF-β1
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Introduction
Diabetic nephropathy is a frequent complication of type 1
and type 2 diabetes mellitus and is currently considered the
leading cause of end-stage renal disease [1]. While
thickening of the glomerular basement membrane, glomer-
ular hypertrophy and mesangial expansion are well known
features of diabetic nephropathy, the pathogenesis of these
alterations is not very clear yet. The DCCT, UK Prospective
Diabetes Study (UKPDS) and Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR Controlled
Evaluation (ADVANCE) studies have shown the role of
hyperglycaemia as a causative factor in the development
and the progression of diabetic nephropathy [2–5]. Never-
theless, hyperglycaemia alone is clearly not sufficient to
account for the heterogeneity and variability of the clinical
appearance of the disorder. Indeed, accumulating evidence
points to critical genetic factors predisposing only a subset
of patients with diabetes to nephropathy [6–8].
Several studies have shown an important involvement of
growth factors and cytokines [9, 10]. In particular, the TGF-
β1 is a key factor in experimental models of diabetic
kidney disease as well as in patients with diabetic
nephropathy [11–15]. In fact, TGF-β1 levels are increased
in diabetic patients and high glucose levels upregulate
expression and bioactivity of TGF-β1 in almost all renal
cell types [11, 12, 16, 17]. Upon binding to its receptor,
TGF-β1 phosphorylates the receptor-regulated SMAD
family members (SMAD)2 and 3, which form oligomeric
complexes with the common SMAD (SMAD 4). These
complexes then translocate into the nucleus, thereby
regulating transcription of target genes, including those
encoding type I and type IV collagen, laminin and
fibronectin [14, 16, 18, 19].
Phosphoprotein enriched in diabetes (PED, also known
as phosphoprotein enriched in astrocytes-15 [PEA-15]) is a
scaffold cytosolic protein originally identified as a major
astrocyte phosphoprotein and found to be widely present in
different tissues [20, 21]. PED plays an important role in
mitogenic and metabolic signalling [21–23]. Gene profiling
studies have shown that PED (also known as PEA15) is
commonly overexpressed in individuals with type 2
diabetes [21, 24]. In cultured muscle and adipose cells
and in peripheral tissues from transgenic mice, forced
production of PED impairs insulin-stimulated GLUT4
translocation and glucose transport, suggesting that PED
may contribute to insulin resistance in type 2 diabetes [25].
Further studies have shown that PED stabilises phospholi-
pase D (PLD) [26] and induces activation of classical
protein kinase C (PKC) isoforms, including PKCα and
PKCβ [23, 27]. The induction of classical PKCs, in turn,
inhibits insulin signalling, at least in skeletal muscle,
adipose and liver cells [28–31]. Nevertheless, the role of
PED in diabetic complications is not known.
In the present work we addressed the question of
whether PED overproduction determines abnormalities in
kidney function and whether it may represent an initial
defect in the progression toward diabetic nephropathy.
Methods
Materials Media, sera, antibiotics for cell culture and the
lipofectamine reagent were from Invitrogen (Grand Island,
NY, USA). The anti-PED polyclonal rabbit antibody and
pcDNA3PED vector have been previously described [21].
pSMAD2/3 (Ser433/435), SMAD2, PKCα, PKCβ, fibro-
nectin, laminin and collagen I and IV antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
SMAD3 was purchased from Calbiochem (San Diego,
CA, USA). Phosphorothioate oligonucleotides antisense
sequences used were as follows: SMAD2 AS: 5′-GCAC
GATGGACGACAT-3′; SMAD2 S: 5′-CAATGCGAGTACG
CGA-3′; SMAD3 AS: 5′-GCAGGATGGACGACAT-3′;
SMAD3 S: 5′-GGAGTCAGACTGACGA-3′; PED anti-
sense oligonucleotides were as previously described [25].
Protein electrophoresis reagents were purchased from Bio-
Rad (Richmond, VA, USA), and western blotting and
enhanced chemiluminescence (ECL) reagents from Amer-
sham Biosciences (Arlington Heights, IL, USA). All other
chemicals were from Sigma Aldrich (St Louis, MO, USA).
Mouse phenotyping Generation of transgenic mice over-
expressing PED (PEDTg) [25] and of Ped/Pea-15 knockout
mice (Ped-KO) bearing ubiquitous ablation of the gene [32]
has been previously described. Homozygous Ped-KO were
used for the study. Both PEDTg and Ped-KO mice were
fertile. Body weight of PEDTg was comparable to that of
wild-type littermates, while, as previously described [32],
Ped-KO displayed a slightly lower body weight. All
procedures described below were approved by the Institu-
tional Animal Care and Utilisation Committee. Animals
were kept in a 12-h dark–light cycle and had free access to
standard diet. Mice chosen for experimentation were
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randomly selected from each box of mice housed in groups
of three to four. Mice were habituated in individual
metabolism cages (Lenderking Caging Products, Millers-
ville, MD, USA) for 24 h. Then, the following variables
were analysed: food intake (g/24 h), water intake (ml/24 h),
urine volume excretion (ml/24 h), urine specific gravity,
urine pH, urine glucose (mg/24 h) and albumin excretion
(μg/24 h). The measurements of blood pressure and heart
rate were performed partially modifying previously de-
scribed methods [33]. Briefly, a 1.0-Fr polyimide pressure
catheter (SPR 1000/2; Millar Instruments, Houston, TX,
USA) was inserted into the left carotid artery and advanced
into the ascending aorta of anaesthetised mice (2%
isoflurane, 98% oxygen). Blood pressure and heart rate
were recorded for 15 min after suspending isoflurane
administration with an 8 channel recorder (Gould Instru-
ments Systems, Cleveland, OH, USA). Data were analysed
using Powerlab and Chart 5 software (AD Instruments,
Sydney, NSW, Australia).
Renal histology and morphometric analysis Kidney sec-
tions were fixed by immersion in Carnoy solution followed
by 4% buffered formaldehyde (vol./vol.) and embedded in
paraffin. The fixed, embedded kidneys were cut into 2 μm
sections and stained with periodic acid–Schiff’s reagent. To
quantify mesangial expansion, sections were coded and
examined by light microscopy by two observers unaware of
the experimental protocol applied. According to previous
reports [34, 35], measurement of the mesangial area of 30
glomeruli randomly selected in each mouse by scanning of
the outer cortex was performed with a computer-aided
manipulator (KS-400; Carl Zeiss Vision, Munich, Germany)
Measurement of serum TGF-β1 and urine albumin Blood
samples of mice were collected from the orbital sinus under
anaesthesia. After centrifugation (800×g) of the blood
samples, TGF-β1 levels in the supernatant fractions were
measured using ELISA kits (R&D System, Minneapolis,
MN, USA). The same kits were used to measure TGF-β1
levels in the media of the cells. Samples of urine collected
through metabolism cages (five samples for each animal;
ten animals/group) were briefly centrifuged at 500×g and
then albumin concentration was determined using ELISA
kits (Bethyl Laboratories, Montgomery, TX, USA).
Tissue collection and primary mouse tubular kidney cell
cultures Tissue samples (kidney) were collected rapidly
after mice were killed by pentobarbitone overdose. Tissues
were snap-frozen in liquid nitrogen and stored at −80°C for
subsequent western blot analysis. Mouse tubular epithelial
cells were isolated as previously described [36]. Cells were
grown until confluent (8 to 12 days) in RPMI 1640 medium
supplemented with 20% fetal calf serum, 2% (wt/vol.) L-
glutamine, 20,000 units/ml penicillin, 20,000 μg/ml strep-
tomycin at 37°C in 5% CO2.
Cell culture procedures and transfection Human kidney 2
(HK2) proximal tubular cells were cultured in RPMI 1640
medium (Invitrogen), containing 11.2 mmol/l glucose sup-
plemented with 10% fetal calf serum, 2% (wt/vol.)
L-glutamine, 10,000 units/ml penicillin, 10,000 μg/ml
streptomycin at 37°C in 5% (vol./vol.) CO2. Stable
transfection of PED cDNA and transient transfection of
antisense oligonucleotides [37] were performed by the
lipofectamine method according to the manufacturer’s instruc-
tions (Invitrogen). For these studies, 60 to 80% confluent cells
were washed twice with Optimem (Invitrogen) and incubated
for 8 h with 5 μg of plasmid construct or antisense
oligonucleotides and 45 to 60 μl of lipofectamine reagent.
The medium was then replaced with DMEM with 10% (vol./
vol.) fetal calf serum and cells further incubated for 15 h
before being assayed. Transfection efficiency for antisense
oligonucleotides was estimated as 45±10% by co-transfection
with green fluorescent protein.
Tissue and cell lysates and immunoblotting Tissue samples
were homogenised in a Polytron (Brinkman Instruments,
Westbury, NY, USA) in 20 ml T-PER reagent (Pierce,
Rockford, IL, USA) per gram of tissue according to
manufacturer’s instructions. After centrifugation at 5000×g
for 5 min, supernatant fraction was collected. Cells were
solubilised in lysis buffer (50 mmol/l HEPES, pH 7.5,
150 mmol/l NaCl, 10 mmol/l EDTA, 10 mmol/l Na4P2O7,
2 mmol/l Na3VO4, 100 mmol/l NaF, 10% (vol./vol.)
glycerol, 1% (vol./vol.) Triton X-100, 1 mmol/l PMSF,
10 mg/ml aprotinin) for 1 h at 4°C and lysates were
centrifuged at 5,000×g for 20 min. Total homogenates were
separated by SDS-PAGE and transferred on to 0.45 μm
Immobilon-P membranes as previously described [38].
Upon incubation with primary and secondary antibodies,
immunoreactive bands were detected by ECL according to
the manufacturer's instructions.
For peripheral blood leucocyte (PBL) separation, EDTA-
treated whole-blood samples were first centrifuged for
10 min at 300×g and the plasma removed. PBLs were
separated using a 6% (vol./vol.) dextran gradient in filtered
PBS, pH 7.4, as previously described [24], washed three
times in PBS, counted and resuspended in 1 ml of PBS for
subsequent use.
Real-time RT-PCR analysis Total cellular RNA was isolat-
ed from whole kidneys of wild-type and PEDTg mice using
a kit (RNeasy; Qiagen, Hilden, Germany) according to
manufacturer’s instructions. Tissue or cell RNA (1 μg) was
reverse-transcribed using Superscript II Reverse Transcrip-
tase (Invitrogen). PCR reactions were analysed using
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SYBR Green mix (Invitrogen). Reactions were performed
using Platinum SYBR Green qPCR Super-UDG and a
multicolour real-time PCR detection system (Cycler IQ;
Bio-Rad). All reactions were performed in triplicate and β-
actin was used as an internal standard. Primer sequences
used were as follows: TGF-β1 (forward) 5′-TGCGC
TTGCAGAGATTAAAA-3′, (reverse) 5′-CTGCCGTACA
ACTCCAGTGA-3′; β-actin (forward) 5′-GCGTGACATC
AAAGAGAAG-3, (reverse) 5′-ACTGTGTTGGCATAG
AGG-3′.
PKC assay For this assay, HK2 cells were deprived of
serum and PKC activity then measured in immunoprecipi-
tates with anti PKCα or PKCβ antibodies, as previously
described [28].
Statistical methods Data were analysed with Statview
software (Abacus Concepts, Piscataway, NJ, USA) by
one-factor analysis of variance. p values of less than 0.05
were considered statistically significant.
Results
Kidney phenotype in PEDTg mice PED was present at
comparable levels in renal cortex and medulla of C57/BL6
mice (Fig. 1a). A 4.5-fold overproduction was detected in
PEDTg mice compared with their wild-type littermates. In
6- and 9-month-old PEDTg mice, urine volume was
increased by about two- and threefold, respectively,
compared with controls, accompanied by a similarly sized
increase of daily urinary albumin excretion (Table 1). No
significant differences were detected in younger animals
(3 months). In addition, at 9 months, plasma creatinine
levels were significantly elevated only in PEDTg. Specific
gravity, urinary pH and glucose and kidney weight, as well
as food and water intake, blood glucose, HbA1c, systolic
and diastolic blood pressure, and heart rate did not show
significant differences at 3, 6 and 9 months of age.
Moreover, consistent with previous reports [25], fasting
insulin, NEFA and triacylglycerol were higher in PEDTg
than in wild-type mice, independently of age. In 9-month-
old PEDTg mice, histological examination of the kidney,
followed by morphometrical analysis, revealed a 2.3-fold
increase of mesangial area compared with their wild-type
littermates (Fig. 1b). Again, no change was detected in 3-
and 6-month-old mice (data not shown). Thus, as well as
deranging glucose tolerance [25], overproduction of PED
induces age-dependent mesangial expansion and affects
renal function in transgenic mice.
TGF-β1 is a cytokine that has been extensively studied
as a major mediator of kidney damage in diabetic
nephropathy [15]. We therefore measured plasma and renal
TGF-β1 levels in PEDTg animals. In 9-month-old PEDTg
mice we saw a greater than twofold increase of circulating
TGF-β1 levels compared with wild-type littermates
(Fig. 1c). Moreover, Tgf-β1 (also known as Tgfb1) mRNA
content was increased by about twofold in kidney extracts
of PEDTg mice (Fig. 1d). Less evident, although signifi-
cant, changes were detected in 6-month-old but not in
3-month-old PEDTg mice.
Effect of PED overexpression on TGF-β1 signalling in HK2
proximal tubular cells To address whether PED directly
regulates TGF-β1 expression in renal cells, HK2 proximal
tubular cells were stably transfected with a PED full-length
cDNA. Several clones were selected and characterised, of
which two, namely those displaying lower (HKPED1) and
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Fig. 1 PED levels, mesangial expansion and TGF-β1 levels/expres-
sion in PEDTg. a Cortex (C) and medulla (M) of the kidneys from
wild-type (WT) and PEDTg were dissected, solubilised and western
blotted with anti-PED antibodies. Blots were revealed by ECL and
autoradiography, and quantified by laser densitometry, as shown in bar
graph. Values were normalised for actin. Each bar represents the mean ±
SD of duplicate determinations in ten mice per group. b Mesangial area
from 9-month-old WT and PEDTg mice was measured as described.
Bars represent mean ± SD of determinations in ten mice per group.
c Serum TGF-β1 levels were determined by ELISA in PEDTg (black
bars) and control mice (white bars) at 3, 6 and 9 months, n=15/group. d
Ped mRNAwas determined by real-time RT-PCR analysis of total RNA
isolated from kidneys of the PEDTg (black bars) and control mice
(white bars), using β-actin as internal standard. Each bar represents the
mean ± SD of four independent experiments in each of which reactions
were performed in triplicate using the pooled total RNAs obtained from
seven mice per genotype. *p<0.05, **p<0.01, ***p<0.001
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higher (HKPED2) PED levels, were studied in detail
(Fig. 2a). TGF-β1 mRNA content was increased by 1.5-
and 2.1-fold, respectively in HKPED1 and HKPED2 cells
(Fig. 2b), while connective tissue growth factor levels did
not change (data not shown). Moreover, TGF-β1 levels
were increased by 2.6- and 3.2-fold in the culture media of
HKPED1 and HKPED2, respectively, compared with the
parental HK2 cells (Fig. 2c). In addition, the amount of
phosphorylated SMAD2/3 in the transfected clones was
higher than in control cells, with no change in the cellular
content of SMAD2 and SMAD3 proteins (Electronic
supplementary material [ESM] Fig. 1), indicating functional
Table 1 Characterisation of wild-type and PEDTg mice
At 3 months At 6 months At 9 months
Variable Wild-type PEDTg Wild-type PEDTg Wild-type PEDTg
Body weight (g) 26±1 25±2 28±1 28±3 30±2 31±2
Food intake (g/day) 2.8±1.1 2.7±1.1 3.0±0.8 3.1±0.4 3.3±0.6 3.5±0.2
Water intake (ml/day) 5.2±0.7 5.5±1.2 5.7±0.7 6.2±1.2 5.8±0.5 6.1±0.8
Urine excretion (ml/day) 1.0±0.05 1.5±0.5 1.1±0.7 2±0.7* 1.2±0.5 3.8±0.7**
Kidney weight (g) 0.23±0.2 0.24±0.2 0.32±0.4 0.31±0.3 0.38±0.2 0.37±0.2
Urine specific gravity 1030±3 1033±2 1032±3 1035±2 1030±3 1035±2
Urine pH 5±0.4 5±0.3 5±0.5 5±0.5 5±0.4 5±0.5
Urine glucose (mg/day) 0.5±0.2 0.5±0.1 0.5±0.4 0.5±0.2 0.5±0.1 0.5±0.3
Urinary albumin excretion (μg/day) 14±3 17±2 15±2 24±3* 14±3 33±3**
Plasma creatinine (μmol/l) 12.4±0.9 14.1±2.6 13.3±1.8 16.8±4.4 12.4±1.8 18.6±3.5***
Fasting blood glucose (mmol/l) 4.4±0.2 4.5±0.1 4.3±0.2 4.4±0.2 5.2±0.4 5.3±0.5
Fasting serum insulin (pmol/l) 63.7±6.8 191±13.8** 72.3±5.2 206.5±10.3** 122.2±8.6 309.8±5.5**
Systolic BP (mmHg) 116±1.4 112±2 118±5.3 117±4 119±3 116±1.7
Diastolic BP (mmHg) 80±0.6 80±0.5 81±1.3 82±0.8 80±1 81±1
Heart rate (beats/min) 384±17.7 377±11.6 361±9 358±14 370±13 374±10
HbA1c (%) 4.5±0.2 4.5±0.3 4±0.4 4.2±0.2 5.2±0.4 5.5±0.3
NEFA (nmol/l) 0.58±0.08 0.82±0.02* 0.53±0.05 0.78±0.06* 0.61±0.05 0.93±0.09*
Triacylglycerol (mmol/l) 0.11±0.03 0.24±0.04* 0.15±0.02 0.26±0.03* 0.19±0.04 0.35±0.03*
Mice were analysed as described in the Methods
Data are the means ± SD of determinations in ten PEDTg and ten wild-type littermates
*p<0.05, **p<0.01, ***p<0.001
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Fig. 2 Effect of PED overexpression on TGF-β1 in HK2 cells. HK2
cells were stably transfected with PED cDNA. HKPED1 and HKPED2
represent two different clones. Cell lysates were analysed by SDS-
PAGE followed by blotting (a) with PED or actin antibodies.
Alternatively (b), the abundance of TGF-β1 mRNA was determined
by real-time RT-PCR analysis, using β-actin as internal standard. c
TGF-β1 levels were measured in the culture medium by ELISA assay.
Bars represent the means ± SD of triplicate measurements in four
independent experiments. *p<0.05, **p<0.01
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activation of the TGF-β1 signalling pathway. Further
supporting this hypothesis, treatment of HK2 cells with
0.1 μmol/l SB431542, a TGF-β1 receptor kinase inhibitor,
reduced SMAD2 and SMAD3 phosphorylation by 40%
(Fig. 3a). A 50% decrease was observed in HKPED2 cells.
Total SMAD2 and SMAD3 levels were unchanged follow-
ing exposure of both cell types to SB431542 (Fig. 3a).
Results consistent with the above were obtained in HKPED1
cells (data not shown).
Effect of PED overexpression on fibronectin production in
HK2 cells TGF-β1 regulates the synthesis of key extracel-
lular matrix proteins, including fibronectin, laminin, and
collagen I and IV [14, 16, 18, 19]. Thus, consistent with the
augmented TGF-β1 production, 1.5- and 1.9-fold increased
levels of fibronectin were detected, independently of
glucose concentration (5.0, 11.2 and 30.0 mmol/l), in the
media of HKPED1 and HKPED2, respectively, compared with
control cells (Fig. 3b). Slight, though not statistically
significant, increases of laminin and both collagen I and
IV were also observed (data not shown).
We have previously shown that overproduction of PED
in cultured cells leads to activation of the PLD/PKC
pathway [23, 27]. To study the possible involvement of
PLD and PKC as potential mediators of PED-induced
fibronectin production, wild-type and HKPED2 cells were
incubated for 15 min with the PLD inhibitor 2-butanol
(0.3% vol./vol.) and with the classical PKC inhibitor
bisindolylmaleimide (BIM) (100 nmol/l) or the specific
PKCβ inhibitor LY379196 (50 nmol/l). At the concen-
pSMAD2/3
SMAD3
SMAD2
β-Actin
**
S
M
A
D
2
/3
 p
h
o
sp
h
o
ry
la
ti
o
n
(%
 o
f 
co
n
tr
o
l)
HK2 HK2
PED2
SB431542 – + – + 
**
F
ib
ro
n
ec
ti
n
 l
ev
el
s
(%
 o
f 
co
n
tr
o
l)
HK2 HK2
PED2
2-But
BIM
LY379196
–
–
–
–
–
–
–
+
+
–
–
– – – –
–
–
–
+SB431542
**
**
**
**
†
–
–
–
–
–
–
–
+
+
–
–
– – – –
–
–
–
+
0
50
100
150
200
0
50
100
150
200
F
ib
ro
n
ec
ti
n
 l
ev
el
s
(%
 o
f 
co
n
tr
o
l)
*
**
HK2
PED1
HK2PED2HK2
*
0
25
125
100
75
50
155
150
200
++
WT PED Tg
**
** **
**
†
F
ib
ro
n
ec
ti
n
 l
ev
el
s
(%
 o
f 
co
n
tr
o
l)
0
50
100
150
200
250
2–But
BIM
LY379196
–
–
–
–
–
–
–
+
+
–
–
– – – –
–
–
–
+SB431542
–
–
–
–
–
–
–
+
+
–
–
– – – –
–
–
–
+
++
a b
c d
Fig. 3 Effect ofPED overexpres-
sion and of PLD, PKC and
TGF-β1 inhibition on fibronectin
production in HK2 cells. a HK2
and HK2PED2 cells were incubat-
ed with SB431542 (0.1 μmol/l).
Total SMAD and actin levels, and
SMAD2/3 phosphorylation were
measured as described. A repre-
sentative autoradiograph of four
independent experiments is
shown, with densitometric analy-
sis of pSMAD2/3:SMAD2 ratio,
normalised for actin levels,
in bar graph. Values are mean ±
SD, **p<0.01. b Culture media
with different glucose concentra-
tions (white bars, 5 mmol/l; black
bars 11.2 mmol/l; grey bars,
30 mmol/l) from control and Ped
overexpressing cells were col-
lected and subjected to western
blot with fibronectin antibodies.
Bands were quantified by laser
densitometry and normalised for
actin of the corresponding cul-
tured cells. Bars represent
means ± SD of three independent
experiments in triplicate.
*p<0.05, **p<0.01. c Culture
media from HK2 and HK2PED2
cells or (d) from murine tubular
epithelial cells isolated from wild-
type (WT) and PEDTg mice were
collected, immunoblotted with
fibronectin antibody. Bands were
quantified by laser densitometry
and normalised for actin of the
corresponding cultured cells. Bars
represent the mean ± SD of
duplicate determinations in five
independent experiments.
**p<0.01; †p<0.01 for differen-
ces between HK2PED2 and HK2
cells
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trations used, these compounds did not inhibit PKCα
(ESM Fig. 2a) and PKCβ (ESM Fig. 2b) activity in
parental HK2 cells. HKPED2 cells displayed higher levels
of PLD (data not shown), PKCα (ESM Fig. 2a) and PKCβ
(ESM Fig. 2b) activity. In these cells, PKCα activity was
unchanged by LY379196 and reduced by 30% and 35%
following exposure to 2-butanol and BIM, respectively.
PKCβ activity was decreased by 30%, 32% and 60%
following exposure to 2-butanol, BIM and LY379196
respectively. Finally, no change of PKCα (ESM Fig. 2a)
and PKCβ (ESM Fig. 2b) activity was induced by
treatment with SB431542, either in HK2 or in HKPED2
cells, indicating that TGF-β1 was not upstream to PKC
activation.
In parallel with the unmodified PKC activity, neither
PLD nor PKC inhibitors reduced fibronectin production by
native HK2 cells (Fig. 3c). In contrast, exposure of HKPED2
cells for 15 min to 0.3% 2-butanol, 100 nmol/l BIM and
50 nmol/l LY379196 decreased fibronectin by 37%, 22%
and 55%, respectively. A similar effect was also observed
following treatment with SB431542 for 15 min, which
reduced fibronectin levels by 40% in HKPED2 cells, without
affecting control cells (Fig. 3c). To confirm these data, we
also measured fibronectin production in primary cultures
from the kidneys of wild-type and PEDTg mice. As shown
in Fig. 3d, exposure to 2-butanol, BIM, LY379196 and
SB431542, respectively reduced the levels of fibronectin by
47%, 38%, 38% and 50% in PEDTg-derived cells only.
Thus, these data indicate that PLD, PKCβ and TGF-β1
signalling are required for regulation of fibronectin release
by cells overexpressing PED.
0
50
100
150
200
HK2 HK2PED2
–
–
–
–
–
–
–
+
+
–
–
2-But
BIM
LY379196
–
–
–
–
–
–
–
+
+
–
–
T
G
F
-β1
 (
p
g
/m
l)
** **
**
†
+ +
a
SMAD2
SMAD3
pSMAD2/3
β-Actin
HK2 HK2PED2
2-But
BIM
LY379196
p
S
M
A
D
 /
S
M
A
D
2
 r
at
io
**
**
**
†
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
–
–
–
–
–
–
–
+
+
–
–
–
–
–
–
–
–
–
+
+
–
–
+ +
b
Fig. 4 Effect of PLD and PKC on TGF-β1 signalling in HK2 cells
overexpressing PED. HK2 and HK2PED2 cells were incubated with 2-
butanol (But), BIM, LY379196 or SB431542 for 15 min. a TGF-β1
levels were measured in the culture media by ELISA assay. Bars
represent means ± SD of triplicate measurements in four independent
experiments. b Cells were solubilised and lysates analysed by SDS-
PAGE and western blotted with total Smad2 or Smad3, p-Smad2/3
and actin antibodies. The autoradiograph shown is representative of
four independent experiments. Densitometric analysis of pSMAD2/3:
SMAD2 ratio is shown in bar graph, with values as mean ± SD. *p<
0.05, **p<0.01; †p<0.05 for differences between HK2PED2 and HK2
PED-SC PED-AS
pSMAD2/3
SMAD3
SMAD2
PED-SC PED-AS
F
ib
ro
n
ec
ti
n
 l
ev
el
s
(%
 o
f 
co
n
tr
o
l)
**
β-Actin
**
T
G
F
-β1
 (
p
g
/m
l)
PED-SC PED-AS
**
p
S
M
A
D
 /
S
M
A
D
2
 r
at
io
PED-SC
PED
100
75
50
25
0
0
20
40
60
80
100
120
β-Actin
0
0.4
0.8
1.2
1.6
2.0
PED-AS
a b
c
d
Fig. 5 Role of PED depletion in TGF-β1 signalling. HK2 cells were
transiently transfected with PED antisense (PED-AS) or scrambled
(PED-SC) oligonucleotides. a PED was detected by western blot, as
previously described. The autoradiograph is representative of four
independent experiments. b TGF-β1 was measured by ELISA. Bars
represent means ± SD of duplicate measurements in four independent
experiments. c Total SMAD2 and SMAD3 levels, and SMAD2/3
phosphorylation were detected by western blot, with densitometric
analysis (bar graph) of pSMAD2/3:SMAD2 ratio. Values are mean ±
SD. d Fibronectin from the culture media of the cells was analysed by
western blot and quantified by bar graph, mean ± SD of duplicate
determinations in four independent experiments. **p<0.01
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Effect of PLD and PKC inhibition on TGF-β1 signalling in
HK2 cells We then measured TGF-β1 production and
function in parental HK2 and in HKPED2 cells following
PLD and PKC inhibition. 2-Butanol and BIM had no
significant effect in the HK2 cells, but reduced TGF-β1
levels in HKPED2 cells by 45% and 40%, respectively
(Fig. 4a). Interestingly, the selective block of PKCβ with
LY379196 led to 65% reduction of TGF-β1 levels in
HKPED2 cells, while being ineffective in HK2 cells. The
effect of PKCβ inhibition was also well detectable in terms
of reduction of SMAD2 phosphorylation, as well as of
SMAD3 (data not shown), with an almost complete block
following treatment with LY379196 of HKPED2 cells
(Fig. 4b).
Role of TGF-β1 signalling in PED-mediated fibronectin
production Next, HK2 cells were transiently transfected
with SMAD2- or SMAD3- specific phosphorothioate anti-
sense oligonucleotides (SMAD2 AS and SMAD3 AS) to
block production of the two proteins. SMAD2 AS and
SMAD3 AS caused a > 70% reduction of SMAD2 and -3
compared with scrambled oligonucleotides, both in wild-
type and in HKPED2 cells (ESM Fig. 3a). Specific depletion
of the SMAD2 and SMAD3 isoforms was followed by a
30% and 35% fibronectin reduction in HK2 cells and by
60% and 65% reductions in HKPED2 clones, compared with
the respective cell clone treated with scrambled control
oligonucleotides (ESM Fig. 3b). Similar results were
obtained in HKPED1 cells (data not shown). Thus, overpro-
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Fig. 6 Determination of serum and renal TGF-β1 levels, and SMAD2/3
phosphorylation in Ped-KO. a Kidneys from wild-type and Ped-KO were
dissected, solubilised and western blotted with anti-PED or actin
antibodies. Blots were revealed by ECL and autoradiography (represen-
tative autoradiograph of four independent experiments). b Serum TGF-
β1 levels were determined in Ped-KO and control mice (n=11 per
group) by ELISA assay. Bars are the mean ± SD of duplicate
determinations. ***p<0.001. c The abundance of Ped mRNA was
determined by real-time RT-PCR analysis of total RNA isolated from
kidneys of the KO and control mice, using β-actin as internal standard.
Bars represent the mean ± SD of four independent experiments in each of
which reactions were performed in triplicate using the pooled total RNAs
obtained from five mice per genotype. ***p<0.001. d Tissue lysates from
kidneys of the KO and control mice (n=5 per group) were pooled and
analysed by SDS-PAGE followed by blotting with total SMAD2 or
SMAD3, p-SMAD2/3 and actin antibodies. The autoradiograph is
representative of three independent experiments, with densitometric
analysis of pSMAD2/3:SMAD2 ratio in bar graph, mean ± SD. **p<0.01
Table 2 Characterisation of wild-type and Ped-KO mice after
streptozotocin treatment
Variables Wild-type Ped-KO
Fasting serum insulin (pmol/l) 70.6±5.2 39.6±8.6**
Fasting blood glucose (mmol/l) 4.0±0.4 4.5±0.5
Body weight (g) 30±2 28±2
Urine excretion (ml/day) 1.4±0.6 1.1±0.2
Urinary albumin excretion (μg/day) 13.4±4 13±2
Plasma creatinine (μmol/l) 11.5±4.4 9.7±4.4
Systolic BP (mmHg) 112±1.7 109±3.8
Diastolic BP (mmHg) 82±0.9 77±0.8
Heart rate (beats/min) 372±15 369±13.9
NEFA (nmol/l) 0.78±0.05 0.82±0.03
Triacylglycerol (mmol/l) 0.20±0.03 0.24±0.04
Mice were analysed as described in the Methods
Data are the means ± SD of determinations in seven wild-type and
seven Ped-KO mice
**p<0.01
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Fig. 7 Correlation between PED levels from PBLs and plasma TGF-
β1 levels in type 2 diabetic patients. PED protein levels were analysed
by western blot in PBLs from 95 type 2 diabetic patients and bands
were quantified by laser densitometry as described. Plasma TGF-β1
levels were measured by ELISA. Linear regression analysis revealed a
positive correlation between PED and TGF-β1 levels (r=0.593,
p<0.001)
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duction of PED upregulated fibronectin production through
a TGF-β1/SMAD2/3-dependent pathway.
PED depletion decreases TGF-β1 signalling and fibronec-
tin production To assess whether endogenous PED controls
TGF-β1 and fibronectin production, HK2 cells were
transiently transfected with a PED-specific phosphoro-
thioate antisense oligonucleotide (PED-AS). PED-AS treat-
ment induced a 65% PED depletion compared with a
scrambled oligonucleotide (PED-SC) (Fig. 5a).
TGF-β1 levels were about 60% lower in PED-AS cells
than in the controls (Fig. 5b) and, in parallel, SMAD2, as
well as SMAD3 (data not shown) phosphorylation was
decreased by about 50% in the presence of the antisense
(Fig. 5c). However, total SMAD protein levels were
unchanged. Consistently, fibronectin secretion was reduced
by about 50% in cells treated with PED-AS compared with
those treated with PED-SC (Fig. 5d). Consistent results were
obtained in Ped-KO [32] (Fig. 6a). In spite of normal glucose
levels (Table 2), Ped gene ablation coincided with a 65% and
60% decrease of TGF-β1 plasma levels and renal mRNA
content, respectively, compared with control mice (Fig. 6b, c).
SMAD2 phosphorylation was also reduced by 40% in
kidney extracts of Ped-KO (Fig. 6d). SMAD3 phosphoryla-
tion also displayed a similar decrease (data not shown).
Correlation between individual levels of PED and plasma
TGFβ in humans We had analysed plasma TGF-β1 levels
and PED protein abundance in PBLs in 95 type 2 diabetic
patients matched for age, BMI, waist circumference,
systolic and diastolic BP, and fasting HDL-cholesterol
[24]. As shown in Fig. 7, there was a positive correlation
between the individual levels of PED and plasma TGF-β1.
Discussion
The molecular mechanisms responsible for the onset and/or
progression of renal complications of diabetes mellitus are
still poorly understood. While hyperglycaemia plays a
crucial role [2–5], other environmental conditions as well
as specific genetic backgrounds may strongly contribute to
the clinical appearance of the disorder, either as protective
or as predisposing factors [39]. A further complicating
element for understanding the molecular determinants is
the lack of animal models fully representative of human
diabetic nephropathy [40]. We have previously generated
a transgenic mouse ubiquitously expressing high levels
of PED, a gene whose expression is elevated in a large
proportion of individuals with type 2 diabetes and in
their first-degree relatives [21, 24]. In mice, PED
overproduction impairs glucose tolerance by affecting
insulin action and secretion [25, 41], and the animals
develop overt diabetes following administration of high-fat
diets [25].
Here we show that PEDTg mice also displayed
mesangial expansion, and mildly elevated plasma creatinine
levels and urinary albumin excretion between 6 and
9 months of age, in the absence of frank hyperglycaemia.
Indeed, blood glucose, systolic and diastolic blood pres-
sure, heart rate and HbA1c did not significantly change in
wild-type and PEDTg mice, when early signs of renal
disorder were found. The renal functional changes were
paralleled by elevation of TGFβ1 levels, a cytokine which
has been commonly found elevated in patients with diabetic
nephropathy [11–15]. However, none of these abnormalities
was detectable in younger littermates, suggesting that while
PED overproduction represents an early defect, it may also
play a role in the slow progression toward renal damage.
Since glucose tolerance of these animals is significantly
reduced, and plasma triacylglycerol and NEFA are in-
creased [25], we cannot exclude the possibility that the
renal abnormalities observed in PEDTg mice could be
linked to the metabolic phenotype. Consistent with this
hypothesis, individuals with impaired glucose tolerance
display a higher risk of developing nephropathy [42], and
microalbuminuria often precedes the onset of diabetes [43].
Nevertheless, studies in HK2 human proximal tubular cells
and in primary cultures from the kidneys have shown that
selective overexpression of PED in kidney cells may, at
least in part, be directly responsible for renal derangement.
In this regard, forced expression of PED increased the
production of extracellular matrix (ECM) proteins, whose
accumulation is a hallmark of mesangial expansion [17]. In
addition, these changes occurred independently of glu-
cose concentration in the extracellular media (Fig. 3b)
and of insulin treatment (data not shown), indicating that
elevation of PED levels is sufficient to impair ECM
production.
The potential mechanisms leading to hyperproduction of
ECM proteins are likely to involve hyperactivation of
PKCβ and the TGF-β1 signalling pathways. PED binds
PLD, increasing its intracellular stability and leading to the
accumulation of diacylglycerol [23, 27]. This, in turn,
determines abnormal activation of conventional PKC iso-
forms, including PKCα and PKCβ. Increased PKCβ
activity may account, at least in part, for the renal
phenotype observed in PEDTg mice. In HK2 cells,
inhibition of PKCβ largely reversed the effect of PED
overexpression. In particular, the increase in TGF-β1
mRNA levels and signalling caused by PED in HK2 cells
was almost completely blocked by the PKCβ inhibitor.
Interestingly, both PKCβ hyperactivity and elevated TGF-
β1 levels are commonly found in diabetic nephropathy,
both in vitro and in vivo [44–46]. In several experimental
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and clinical studies, inhibition of PKC (LY333531) has
been shown to delay or halt the progression of diabetic
complications [47]. Part of the beneficial effect of PKC
inhibition is due to the consequent downregulation of TGF-
β1 [48]. Consistently, higher circulating levels of TGF-β1
have been detected in PEDTg mice and are paralleled by
increased Tgf-β1 mRNA content in kidney extracts.
However, the question of whether other cell types contrib-
ute to the increase of TGF-β1 content in the bloodstream is
currently not resolved and under investigation in our
laboratory.
Inhibition of PLD and PKCβ, as well as of TGF-β1
receptor activity, or genetic silencing of SMAD2 and
SMAD3 decreased production of fibronectin. Thus, PED
overexpression may lead to increased PKCβ activity, which
enhances expression of TGF-β1, which in turn upregulates
fibronectin production. Further support of this hypothesis
was seen in the fact that inhibition of PED by antisense
oligonucleotides in HK2 cells was paralleled by reduced
PKCβ activity and TGF-β1 expression and signalling, as
well as by decreased fibronectin production. Similarly to
PED-depleted cells, kidney and total TGF-β1 levels and
PKCβ activity were reduced in animals bearing the
complete ablation of Ped gene, indicating a cause–effect
relationship.
It remains unknown whether PED overproduction is
involved in diabetic nephropathy in humans. However, in
a cohort of patients with type 2 diabetes [24], we found a
positive correlation between levels of PED measured in
PBLs and plasma TGFβ1 levels. It could therefore be
inferred that high expression levels of PED deranges renal
function in a subset of diabetic individuals, thereby
facilitating the onset and/or progression of diabetic
nephropathy.
The mechanism leading to the increase of PED cellular
levels are only partially known and may be due to altered
transcriptional control [49] or to post-translational modifi-
cations [50]. The contribution of genetic variations and
epigenetic modifications is currently under investigation in
our laboratory.
Thus, high expression levels of PED determine an
increase of PKCβ activity and of TGF-β1 expression in
cellular and animal models, as well as in humans. They
therefore may represent an early abnormality, contributing
to the derangement of ECM deposition and to progression
toward nephropathy.
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